[1] Ommen SR., Mital S., Burke MA., Day SM., Deswal A., Elliott P., Evanovich LL., Hung J., Joglar JA., Kantor P., et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2020; 76(25): e159–240. Doi: 10.1016/j.jacc.2020.08.045.
[2] Writing Committee Members., Ommen SR., Ho CY., Asif IM., Balaji S., Burke MA., Day SM., Dearani JA., Epps KC., Evanovich L., et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2024; 83(23): 2324–405. Doi: 10.1016/j.jacc.2024.02.014.
[3] Elliot P., Zamorano JL., Anastasakis A., Borger MA., Borggrefe M., Cecchi F., Charron P., Hagege AA., Lafont A., Limongelli G., et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: The task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014; 35(39): 2733–79. Doi: 10.1093/eurheartj/ehu284.
[4] Lipshultz SE., Law YM., Asante-Korang A., Austin ED., Dipchand AI., Everitt MD., Hsu DT., Lin KY., Price JF., Wilkinson JD., et al. Cardiomyopathy in Children: Classification and Diagnosis: A Scientific Statement From the American Heart Association. Circulation 2019; 140(1): E9–68. Doi: 10.1161/CIR.0000000000000682.
[5] Bogle C., Colan SD., Miyamoto SD., Choudhry S., Baez-Hernandez N., Brickler MM., Feingold B., Lal AK., Lee TM., Canter CE., et al. Treatment Strategies for Cardiomyopathy in Children: A Scientific Statement From the American Heart Association. Circulation 2023; 148(2): Epub ahead of print. Doi: 10.1161/CIR.0000000000001151.
[6] Gurschenkov A., Andreeva S., Zaitsev V., Khazov P., Ischmukhametov G., Kozyreva A., Sokolnikova P., Moiseeva O., Kostareva A., Gordeev M. Septal Myectomy in Patients with Hypertrophic Cardiomyopathy and Nonclassical Anderson-Fabry Disease. J Cardiovasc Dev Dis 2024; 11(9): 293. Doi: 10.3390/JCDD11090293.
[7] Colan SD., Lipshultz SE., Lowe AM., Sleeper LA., Messere J., Cox GF., Lurie PR., Orav EJ., Towbin JA. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry. Circulation 2007; 115(6): 773–81. Doi: 10.1161/CIRCULATIONAHA.106.621185.
[8] Monda E., Rubino M., Lioncino M., Di Fraia F., Pacileo R., Verrillo F., Cirillo A., Caiazza M., Fusco A., Esposito A., et al. Hypertrophic Cardiomyopathy in Children: Pathophysiology, Diagnosis, and Treatment of Non-sarcomeric Causes. Front Pediatr 2021; 9: 632293. Doi: 10.3389/FPED.2021.632293.
[9] Фетисова СГ., Мельник ОВ., Фомичева ЮВ., Сокольникова ПС., Аббясова ВГ., Федорова ОВ., Костарева АА., Васичкина ЕС. Сравнительная информативность применения различных таргетных панелей при генетической диагностике гипертрофической кардиопатии у детей. Трансляционная Медицина 2025; 12(1): 6–14.
[10] Limongelli G., Adorisio R., Baggio C., Bauce B., Biagini E., Castelletti S., Favilli S., Imazio M., Lioncino M., Merlo M., et al. Diagnosis and Management of Rare Cardiomyopathies in Adult and Paediatric Patients. A Position Paper of the Italian Society of Cardiology (SIC) and Italian Society of Paediatric Cardiology (SICP). Int J Cardiol 2022; 357: 55–71. Doi: 10.1016/J.IJCARD.2022.03.050.
[11] Alfares AA., Kelly MA., McDermott G., Funke BH., Lebo MS., Baxter SB., Shen J., McLaughlin HM., Clark EH., Babb LJ., et al. Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: Expanded panels offer limited additional sensitivity. Genet Med 2015; 17(11): 880–8. Doi: 10.1038/gim.2014.205.
[12] Ingles J., Sarina T., Yeates L., Hunt L., Macciocca I., Mccormack L., Winship I., Mcgaughran J., Atherton J., Semsarian C. Clinical predictors of genetic testing outcomes in hypertrophic cardiomyopathy. Genet Med 2013; 15(12): 972–7. Doi: 10.1038/GIM.2013.44.
[13] Geisterfer-Lowrance AAT., Kass S., Tanigawa G., Vosberg HP., McKenna W., Seidman CE., Seidman JG. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell 1990; 62(5): 999–1006. Doi: 10.1016/0092-8674(90)90274-I.
[14] Seidman JG., Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 2001; 104(4): 557–67. Doi: 10.1016/S0092-8674(01)00242-2.
[15] Seidman CE., Seidman JG. Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: a personal history. Circ Res 2011; 108(6): 743–50. Doi: 10.1161/CIRCRESAHA.110.223834.
[16] Liew AC., Vassiliou VS., Cooper R., Raphael CE. Hypertrophic Cardiomyopathy-Past, Present and Future. J Clin Med 2017; 6(12): 118. Doi: 10.3390/JCM6120118.
[17] Maron BA., Wang RS., Carnethon MR., Rowin EJ., Loscalzo J., Maron BJ., Maron MS. What Causes Hypertrophic Cardiomyopathy? Am J Cardiol 2022; 179: 74–82. Doi: 10.1016/j.amjcard.2022.06.017.
[18] Maron BJ., Ommen SR., Semsarian C., Spirito P., Olivotto I., Maron MS. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol 2014; 64(1): 83–99. Doi: 10.1016/J.JACC.2014.05.003.
[19] Шляхто ЕВ., Семернин ЕН., Гудкова АЯ., Костарева АА. Первичные кардиомиопатии, современное представление. Терапевтический Архив 2005; 77(12): 77–83.
[20] Gersh BJ., Maron BJ., Bonow RO., Dearani JA., Fifer MA., Link MS., Naidu SS., Nishimura RA., Ommen SR., Rakowski H., et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary: A report of the American College of cardiology foundation/American heart association task force on practice guidelines. Circulation 2011; 124(24): 2761–96. Doi: 10.1161/CIR.0b013e318223e230.
[21] Kelly MA., Caleshu C., Morales A., Buchan J., Wolf Z., Harrison SM., Cook S., Dillon MW., Garcia J., Haverfield E., et al. Adaptation and validation of the ACMG/AMP variant classification framework for MYH7-associated inherited cardiomyopathies: Recommendations by ClinGen’s Inherited Cardiomyopathy Expert Panel. Genet Med 2018; 20(3): 351–9. Doi: 10.1038/gim.2017.218.
[22] Lopes LR., Murphy C., Syrris P., Dalageorgou C., McKenna WJ., Elliott PM., Plagnol V. Use of high-throughput targeted exome-sequencing to screen for copy number variation in hypertrophic cardiomyopathy. Eur J Med Genet 2015; 58(11): 611–6. Doi: 10.1016/j.ejmg.2015.10.001.
[23] Maron BJ., Maron MS., Maron BA., Loscalzo J. Moving Beyond the Sarcomere to Explain Heterogeneity in Hypertrophic Cardiomyopathy: JACC Review Topic of the Week. J Am Coll Cardiol 2019; 73(15): 1978–86. Doi: 10.1016/j.jacc.2019.01.061.
[24] Zhou N., Qin S., Liu Y., Tang L., Zhao W., Pan C., Qiu Z., Wang X., Shu X. Whole-exome sequencing identifies rare compound heterozygous mutations in the MYBPC3 gene associated with severe familial hypertrophic cardiomyopathy. Eur J Med Genet 2018; 61(8): 434–41. Doi: 10.1016/j.ejmg.2018.03.001.
[25] Давыдова ВГ., Гудкова АЯ., Крутиков АН., Полякова АА., Костарева АА. Клинические, морфологические и генетические характеристики пациентов молодого возраста с гипертрофической кардиомиопатией, имеющих показания к имплантации кардиовертера-дефибриллятора. Российский Кардиологический Журнал 2024; 29(11): 5994. Doi: https://doi.org/10.15829/1560-4071-2024-5994.
[26] Kostareva A., Gudkova A., Sjöberg G., Mörner S., Semernin E., Krutikov A., Shlyakhto E., Sejersen T. Deletion in TNNI3 gene is associated with restrictive cardiomyopathy. Int J Cardiol 2009; 131(3): 410–2. Doi: 10.1016/j.ijcard.2007.07.108.
[27] Туральчук МВ., Новик ГА., Гудкова АЯ. Особенности течения кардиомиопатий с рестриктивным фенотипом, обусловленных мутациями генов сердечного тропонина I и десмина, и алгоритмы их диагностики. Педиатрическая Фармакология 2011; 8(4): 112–6.
[28] Ho CY., Day SM., Colan SD., Russell MW., Towbin JA., Sherrid M V., Canter CE., Jefferies JL., Murphy AM., Cirino AL., et al. The burden of early phenotypes and the influence of wall thickness in hypertrophic cardiomyopathy mutation carriers: Findings from the HCMNet study. JAMA Cardiol 2017; 2(4): 419–28. Doi: 10.1001/jamacardio.2016.5670.
[29] Tsaturyan AK., Zaklyazminskaya E V., Polyak ME., Kopylova G V., Shchepkin D V., Kochurova AM., Gonchar AD., Kleymenov SY., Koubasova NA., Bershitsky SY., et al. De Novo Asp219Val Mutation in Cardiac Tropomyosin Associated with Hypertrophic Cardiomyopathy. Int J Mol Sci 2022; 24(1): 18. Doi: 10.3390/IJMS24010018.
[30] Ansari-Lari MA., Ali SZ. Fine-Needle Aspiration of Abdominal Fat Pad for Amyloid Detection: A Clinically Useful Test? Diagn Cytopathol 2004; 30(3): 178–81. Doi: 10.1002/dc.10370.
[31] Canepa M., Sorensen LL., Pozios I., Dimaano VL., Luo HC., Pinheiro AC., Strait JB., Brunelli C., Abraham MR., Ferrucci L., et al. Comparison of clinical presentation, left ventricular morphology, hemodynamics, and exercise tolerance in obese versus nonobese patients with hypertrophic cardiomyopathy. Am J Cardiol 2013; 112(8): 1182–9. Doi: 10.1016/j.amjcard.2013.05.070.
[32] Hodatsu A., Konno T., Hayashi K., Funada A., Fujita T., Nagata Y., Fujino N., Kawashiri MA., Yamagishi M. Compound heterozygosity deteriorates phenotypes of hypertrophic cardiomyopathy with founder MYBPC3 mutation: Evidence from patients and zebrafish models. Am J Physiol - Hear Circ Physiol 2014; 307(11): H1594–604. Doi: 10.1152/ajpheart.00637.2013.
[33] Charron P., Arad M., Arbustini E., Basso C., Bilinska Z., Elliott P., Helio T., Keren A., McKenna WJ., Monserrat L., et al. Genetic counselling and testing in cardiomyopathies: A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2010; 31(22): 2715–28. Doi: 10.1093/eurheartj/ehq271.
[34] Finocchiaro G., Magavern E., Sinagra G., Ashley E., Papadakis M., Tome-Esteban M., Sharma S., Olivotto I. Impact of demographic features, lifestyle, and comorbidities on the clinical expression of hypertrophic cardiomyopathy. J Am Heart Assoc 2017; 6(12): e007161. Doi: 10.1161/JAHA.117.007161.
[35] Blagova O., Alieva I., Kogan E., Zaytsev A., Sedov V., Chernyavskiy S., Surikova Y., Kotov I., Zaklyazminskaya E V. Mixed Hypertrophic and Dilated Phenotype of Cardiomyopathy in a Patient With Homozygous In-Frame Deletion in the MyBPC3 Gene Treated as Myocarditis for a Long Time. Front Pharmacol 2020; 11: 579450. Doi: 10.3389/FPHAR.2020.579450.
[36] Pasquale F., Syrris P., Kaski JP., Mogensen J., McKenna WJ., Elliott P. Long-term outcomes in hypertrophic cardiomyopathy caused by mutations in the cardiac troponin T gene. Circ Cardiovasc Genet 2012; 5(1): 10–7. Doi: 10.1161/CIRCGENETICS.111.959973.
[37] Maron BJ., Kragel AH., Roberts WC. Sudden death in hypertrophic cardiomyopathy with normal left ventricular mass. Br Heart J 1990; 63(5): 308–10. Doi: 10.1136/HRT.63.5.308.
[38] Walsh R., Buchan R., Wilk A., John S., Felkin LE., Thomson KL., Chiaw TH., Loong CCW., Pua CJ., Raphael C., et al. Defining the genetic architecture of hypertrophic cardiomyopathy: re-evaluating the role of non-sarcomeric genes. Eur Heart J 2017; 38(46): 3461–8. Doi: 10.1093/EURHEARTJ/EHW603.
[39] Hypertrophic Cardiomyopathy Gene Curation Expert Panel - ClinGen | Clinical Genome Resource. https://clinicalgenome.org/affiliation/40008/. [accessed July 25, 2023].
[40] Marian AJ., Braunwald E. Hypertrophic cardiomyopathy: Genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res 2017; 121(7): 749–70. Doi: 10.1161/CIRCRESAHA.117.311059.
[41] Ingles J., Goldstein J., Thaxton C., Caleshu C., Corty EW., Crowley SB., Dougherty K., Harrison SM., McGlaughon J., Milko L V., et al. Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes. Circ Genomic Precis Med 2019; 12(2): 57–64. Doi: 10.1161/CIRCGEN.119.002460.
[42] Bagnall RD., Ingles J., Dinger ME., Cowley MJ., Ross SB., Minoche AE., Lal S., Turner C., Colley A., Rajagopalan S., et al. Whole Genome Sequencing Improves Outcomes of Genetic Testing in Patients With Hypertrophic Cardiomyopathy. J Am Coll Cardiol 2018; 72(4): 419–29. Doi: 10.1016/J.JACC.2018.04.078.
[43] Maron BJ. Clinical Course and Management of Hypertrophic Cardiomyopathy. N Engl J Med 2018; 379(7): 655–68. Doi: 10.1056/NEJMRA1710575.
[44] Aslam F., Haque A., Foody JA., Shirani J. The frequency and functional impact of overlapping hypertension on hypertrophic cardiomyopathy: a single-center experience. J Clin Hypertens (Greenwich) 2010; 12(4): 240–5. Doi: 10.1111/J.1751-7176.2009.00251.X.
[45] Timmis A., Gale CP., Flather M., Maniadakis N., Vardas P. Cardiovascular disease statistics from the European atlas: inequalities between high- and middle-income member countries of the ESC. Eur Hear Journal Qual Care Clin Outcomes 2018; 4(1): 1–3. Doi: 10.1093/EHJQCCO/QCX045.
[46] Lopes LR., Losi M-A., Sheikh N., Laroche C., Charron P., Gimeno J., Kaski JP., Maggioni AP., Tavazzi L., Arbustini E., et al. Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy/Myocarditis registry. Eur Hear Journal Qual Care Clin Outcomes 2022; 9(1): 42–53. Doi: 10.1093/EHJQCCO/QCAC006.
[47] De La Rosa A., Shah M., Shiota T., Siegel R., Rader F. Comparing echocardiographic characteristics in genotype positive-phenotype positive hypertrophic cardiomyopathy and hypertensive left ventricular hypertrophy. Eur Hear Journal Cardiovasc Imaging 2022; 23(3): 340–8. Doi: 10.1093/EHJCI/JEAB217.
[48] Gil TCP., Castier MB., Gondar AFP., Sales AF., Santos M de O., de Lima FC da S., Mourilhe-Rocha R. Strain Analysis of Left Ventricular Function in the Association of Hypertrophic Cardiomyopathy and Systemic Arterial Hypertension. Arq Bras Cardiol 2019; 113(4): 677–84. Doi: 10.5935/ABC.20190176.
[49] Harper AR., Goel A., Grace C., Thomson KL., Petersen SE., Xu X., Waring A., Ormondroyd E., Kramer CM., Ho CY., et al. Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity. Nat Genet 2021; 53(2): 135–42. Doi: 10.1038/S41588-020-00764-0.
[50] Wang Z., Zheng Y., Ruan H., Li L., Zhang M., Duan L., He S. The impact of hypertension on the prognosis of patients with hypertrophic cardiomyopathy: a single-center retrospective study. PeerJ 2023; 11: e14614. Doi: 10.7717/PEERJ.14614.
[51] Zhang Y., Liu M-H., Zhang M., Wu G-X., Liu J., Wang J-Z., Sun X-L., Jiang W., Wang D., Kang L-M., et al. Different clinical characteristics and outcomes of hypertrophic cardiomyopathy with and without hypertension: seeking the truth. J Geriatr Cardiol 2023; 20(2): 109. Doi: 10.26599/1671-5411.2023.02.007.
[52] Gruner C., Ivanov J., Care M., Williams L., Moravsky G., Yang H., Laczay B., Siminovitch K., Woo A., Rakowski H. Toronto hypertrophic cardiomyopathy genotype score for prediction of a positive genotype in hypertrophic cardiomyopathy. Circ Cardiovasc Genet 2013; 6(1): 19–26. Doi: 10.1161/CIRCGENETICS.112.963363.
[53] Ежова АВ., Зайцев ВВ., Ишмухаметов ГИ., Андреева СЕ., Антонова АП., Даутов ДР., Конасов КС., Гурщенков АВ., Гордеев МЛ., Костарева АА., et al. Значение традиционных факторов риска сердечно-сосудистых заболеваний в фенотипических проявлениях гипертрофической кардиомиопатии. Артериальная Гипертензия 2023; 29(4): 371–9. Doi: 10.18705/1607-419X-2023-29-4-371-379.
[54] Luo Q., Chen J., Zhang T., Tang X., Yu B. Retrospective analysis of clinical phenotype and prognosis of hypertrophic cardiomyopathy complicated with hypertension. Sci Rep 2020; 10(1). Doi: 10.1038/S41598-019-57230-Z.
[55] Ingles J., Burns C., Bagnall RD., Lam L., Yeates L., Sarina T., Puranik R., Briffa T., Atherton JJ., Driscoll T., et al. Nonfamilial Hypertrophic Cardiomyopathy: Prevalence, Natural History, and Clinical Implications. Circ Cardiovasc Genet 2017; 10(2): e001620. Doi: 10.1161/CIRCGENETICS.116.001620.
[56] Maron BJ., Wolfson JK., Epstein SE., Roberts WC. Intramural (“small vessel”) coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol 1986; 8(3): 545–57. Doi: 10.1016/S0735-1097(86)80181-4.
[57] Rowin EJ., Maron BJ., Maron MS. The Hypertrophic Cardiomyopathy Phenotype Viewed Through the Prism of Multimodality Imaging: Clinical and Etiologic Implications. JACC Cardiovasc Imaging 2020; 13(9): 2002–16. Doi: 10.1016/J.JCMG.2019.09.020.
[58] Bonaventura J., Rowin EJ., Maron MS., Maron BJ. Is Hypertrophic Cardiomyopathy Always a Familial and Inherited Disease? J Am Heart Assoc 2023; 12(12): e028974. Doi: 10.1161/JAHA.122.028974.
[59] Burton D., Abdulrazzak H., Knott A., Elliott K., Redwood C., Watkins H., Marston S., Ashley C. Two mutations in troponin I that cause hypertrophic cardiomyopathy have contrasting effects on cardiac muscle contractility. Biochem J 2002; 362(2): 443–51. Doi: 10.1042/0264-6021:3620443.
[60] Бокерия ЛА., Гудкова АЯ., Созин СЕ., Семернин ЕН., Борисов КВ., Чухловин АБ., Тотолян АА., Рыбакова МГ., Шляхто ЕВ. Экспрессия генов матриксной металлопротеиназы-1 (ММР-1), тканевого ингибитора матриксных металлопротеиназ-1 (TIMP-1), коллагена I и III типов в миокарде больных идиопатической гипертрофической кардиомиопатией. Бюллетень НЦССХ Им АН Бакулева РАМН 2005; 6(4): 35–42.
[61] Гудкова АЯ. Характеристика течения обструктивной гипертрофической кардиомиопатии у взрослых (обзор литературы и результаты собственных исследований). Артериальная Гипертензия 2008; 14(2, Приложение 2): 39–49.
[62] Гудкова АЯ., Рыбакова МГ., Бокерия ЛА., Шляхто ЕВ. Гипертрофическая кардиомиопатия. Клинико-морфологические сопоставления. Архив Патологии 2012; 74(4): 8–11.
[63] Гудкова АЯ., Шляхто ЕВ. Клеточные механизмы гипертрофии миокарда при гипертрофической кардиомиопатии и эссенциальной артериальной гипертензии. Артериальная Гипертензия 2008; 14(4): 364–80.
[64] Philipson DJ., DePasquale EC., Yang EH., Baas AS. Emerging pharmacologic and structural therapies for hypertrophic cardiomyopathy. Heart Fail Rev 2017; 22(6): 879–88. Doi: 10.1007/s10741-017-9648-x.
[65] Roberts R., Sigwart U. Current concepts of the pathogenesis and treatment of hypertrophic cardiomyopathy. Circulation 2005; 112(2): 293–6. Doi: 10.1161/01.CIR.0000146788.30724.0A.
[66] Зайцев ВВ., Гурщенков АВ., Митрофанова ЛБ., Рыжков АВ., Казакова ЕЕ., Бадаев КД., Гордеев МЛ., Моисеева ОМ. Клиническое значение различных методов оценки миокардиального фиброза при гипертрофической кардиомиопатии. Кардиология 2020; 60(3): 44–50. Doi: 10.18087/cardio.2020.3.n561.
[67] Arbelo E., Protonotarios A., Gimeno JR., Arbustini E., Arbelo E., Barriales-Villa R., Basso C., Biagini E., Blom NA., De Boer RA., et al. 2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC). Eur Heart J 2023; 44(37): 3503–626. Doi: 10.1093/EURHEARTJ/EHAD194.
[68] Arbustini E., Narula N., Dec GW., Reddy KS., Greenberg B., Kushwaha S., Marwick T., Pinney S., Bellazzi R., Favalli V., et al. The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: Endorsed by the world heart federation. J Am Coll Cardiol 2013; 62(22): 2046–72. Doi: 10.1016/j.jacc.2013.08.1644.
[69] Bokhari S., Castaño A., Pozniakoff T., Deslisle S., Latif F., Maurer MS. 99mTc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 2013; 6(2): 195–201. Doi: 10.1161/CIRCIMAGING.112.000132.
[70] Charron P., Villard E., Sébillon P., Laforêt P., Maisonobe T., Duboscq-Bidot L., Romero N., Drouin-Garraud V., Frébourg T., Richard P., et al. Danon’s disease as a cause of hypertrophic cardiomyopathy: A systematic survey. Heart 2004; 90(8): 842–6. Doi: 10.1136/hrt.2003.029504.
[71] Frustaci A., Chimenti C., Doheny D., Desnick RJ. Evolution of cardiac pathology in classic Fabry disease: Progressive cardiomyocyte enlargement leads to increased cell death and fibrosis, and correlates with severity of ventricular hypertrophy. Int J Cardiol 2017; 248: 257–62. Doi: 10.1016/j.ijcard.2017.06.079.
[72] Tsai SB., Seldin DC., Wu H., O’Hara C., Ruberg FL., Sanchorawala V. Myocardial infarction with “clean coronaries” caused by amyloid light-chain AL amyloidosis: A case report and literature review. Amyloid 2011; 18(3): 160–4. Doi: 10.3109/13506129.2011.571319.
[73] Wilkinson JD., Lowe AM., Salbert BA., Sleeper LA., Colan SD., Cox GF., Towbin JA., Connuck DM., Messere JE., Lipshultz SE. Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: A study from the Pediatric Cardiomyopathy Registry. Am Heart J 2012; 164(3): 442–8. Doi: 10.1016/j.ahj.2012.04.018.
[74] Frustaci A., Russo MA., Chimenti C. Diagnostic contribution of left ventricular endomyocardial biopsy in patients with clinical phenotype of hypertrophic cardiomyopathy. Hum Pathol 2013; 44(1): 133–41. Doi: 10.1016/j.humpath.2012.04.023.
[75] Cook A., Giunti P. Friedreich’s ataxia: Clinical features, pathogenesis and management. Br Med Bull 2017; 124(1): 19–30. Doi: 10.1093/bmb/ldx034.
[76] Dubrey SW., Hawkins PN., Falk RH. Amyloid diseases of the heart: Assessment, diagnosis, and referral. Heart 2011; 97(1): 75–84. Doi: 10.1136/hrt.2009.190405.
[77] Planté-Bordeneuve V., Said G. Familial amyloid polyneuropathy. Lancet Neurol 2011; 10(12): 1086–97. Doi: 10.1016/S1474-4422(11)70246-0.
[78] European Reference Networks in the Field of Rare Diseases: State of the Art and Future Directions. Third Report. http://www.eucerd.eu/?post_type=document&p=1204. [accessed June 29, 2020].
[79] Ibrahim M., Rao C., Ashrafian H., Chaudhry U., Darzi A., Athanasiou T. Modern Management of Systolic Anterior Motion of the Mitral Valve. Eur J Cardiothorac Surg 2012; 41: 60–70.
[80] Deng L., Huang X., Yang C., Lyu B., Duan F., Tang D., Song Y. Numerical simulation study on systolic anterior motion of the mitral valve in hypertrophic obstructive cardiomyopathy. Int J Cardiol 2018; 266: 167–73. Doi: 10.1016/j.ijcard.2018.01.062.
[81] Manabe S., Kasegawa H., Arai H., Takanashi S. Management of systolic anterior motion of the mitral valve: a mechanism-based approach. Gen Thorac Cardiovasc Surg 2018; 66(7): 379–89. Doi: 10.1007/s11748-018-0915-0.
[82] Ro R., Halpern D., Sahn DJ., Homel P., Arabadjian M., Lopresto C., Sherrid M V. Vector flow mapping in obstructive hypertrophic cardiomyopathy to assess the relationship of early systolic left ventricular flow and the mitral valve. J Am Coll Cardiol 2014; 64(19): 1984–95. Doi: 10.1016/j.jacc.2014.04.090.
[83] Hymel BJ., Townsley MM. Echocardiographic assessment of systolic anterior motion of the mitral valve. Anesth Analg 2014; 118(6): 1197–201. Doi: 10.1213/ANE.0000000000000196.
[84] Sherrid M V., Gunsburg DZ., Moldenhauer S., Pearle G. Systolic anterior motion begins at low left ventricular outflow tract velocity in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2000; 36(4): 1344–54. Doi: 10.1016/S0735-1097(00)00830-5.
[85] Silbiger JJ. Abnormalities of the Mitral Apparatus in Hypertrophic Cardiomyopathy: Echocardiographic, Pathophysiologic, and Surgical Insights. J Am Soc Echocardiogr 2016; 29(7): 622–39. Doi: 10.1016/j.echo.2016.03.003.
[86] Shah JS., Esteban MTT., Thaman R., Sharma R., Mist B., Pantazis A., Ward D., Kohli SK., Page SP., Demetrescu C., et al. Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy. Heart 2008; 94(10): 1288–94. Doi: 10.1136/hrt.2007.126003.
[87] Geske JB., Sorajja P., Ommen SR., Nishimura RA. Variability of left ventricular outflow tract gradient during cardiac catheterization in patients with hypertrophic cardiomyopathy. JACC Cardiovasc Interv 2011; 4(6): 704–9. Doi: 10.1016/j.jcin.2011.02.014.
[88] Efthimiadis GK., Pagourelias ED., Parcharidou D., Gossios T., Kamperidis V., Theoflogiannakos EK., Pappa Z., Meditskou S., Hadjimiltiades S., Pliakos C., et al. Clinical characteristics and natural history of hypertrophic cardiomyopathy with midventricular obstruction. Circ J 2013; 77(9): 2366–74. Doi: 10.1253/circj.CJ-12-1561.
[89] Minami Y., Kajimoto K., Terajima Y., Yashiro B., Okayama D., Haruki S., Nakajima T., Kawashiro N., Kawana M., Hagiwara N. Clinical implications of midventricular obstruction in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2011; 57(23): 2346–55. Doi: 10.1016/j.jacc.2011.02.033.
[90] Yan LR., Zhao SH., Wang HY., Duan FJ., Wang ZM., Yang YJ., Guo XY., Cai C., Xua ZM., Lia YS., et al. Clinical characteristics and prognosis of 60 patients with midventricular obstructive hypertrophic cardiomyopathy. J Cardiovasc Med 2015; 16(11): 751–60. Doi: 10.2459/JCM.0000000000000163.
[91] Hang D., Schaff H V., Ommen SR., Dearani JA., Nishimura RA. Combined transaortic and transapical approach to septal myectomy in patients with complex hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg 2018; 155(5): 2096–102. Doi: 10.1016/j.jtcvs.2017.10.054.
[92] Pacheco Claudio C., Quesada O., Pepine CJ., Noel Bairey Merz C. Why names matter for women: MINOCA/INOCA (myocardial infarction/ischemia and no obstructive coronary artery disease). Clin Cardiol 2018; 41(2): 185–93. Doi: 10.1002/clc.22894.
[93] Аверкина НВ., Габрусенко СА., Овчинников АГ., Наумов ВГ., Самойленко, Л.Е. Сергиенко В. Оценка перфузии миокарда у больных с гипертрофической кардиомиопатией в сопоставлении с клиническими и эхокардиографическими данными. Терапевтический Архив 2003; 75(4): 20–5.
[94] Аверков ОВ., Барбараш ОЛ., Бойцов СА., Васильева ЕЮ., Драпкина ОМ., Галявич АС., Гиляров МЮ., Зайратьянц ОВ., Кактурский ЛВ., Карпов ЮА., et al. Дифференцированный подход в диагностике, формулировке диагноза, ведении больных и статистическом учете инфаркта миокарда 2 типа (согласованная позиция). Российский Кардиологический Журнал 2019; 24(6): 7–21.
[95] Каплунова ВЮ., Шакарьянц ВА., Кожевникова МВ., Ильгисонис ИС., Привалова ЕВ., Хабарова НВ., Найманн ЮН., Беленков ЮИ., Шакарьянц ВА. Гипертрофическая кардиомиопатия и ишемическая болезнь сердца. Варианты сочетанной патологии. Кардиология 2017; 57(12): 16–24.
[96] Костин СИ. Морфологические и морфометрические особенности гипертрофической кардиомиопатии. Архив Патологии 1989; 51(1): 47–52.
[97] Мухарлямов Н. Кардиомиопатии. Москва; 1990.
[98] Aletras AH., Tilak GS., Hsu LY., Arai AE. Heterogeneity of intramural function in hypertrophic cardiomyopathy mechanistic insights from MRI late gadolinium enhancement and high-resolution displacement encoding with stimulated echoes strain maps. Circ Cardiovasc Imaging 2011; 4(4): 425–34. Doi: 10.1161/CIRCIMAGING.110.958751.
[99] Camici PG., Olivotto I., Rimoldi OE. The coronary circulation and blood flow in left ventricular hypertrophy. J Mol Cell Cardiol 2012; 52(4): 857–64. Doi: 10.1016/j.yjmcc.2011.08.028.
[100] Einarsen E., Cramariuc D., Lønnebakken MT., Boman K., Gohlke-Bärwolf C., Chambers JB., Gerdts E. Comparison of Frequency of Ischemic Cardiovascular Events in Patients With Aortic Stenosis With Versus Without Asymmetric Septal Hypertrophy (from the SEAS Trial). Am J Cardiol 2017; 119(7): 1082–7. Doi: 10.1016/j.amjcard.2016.11.064.
[101] Foà A., Agostini V., Rapezzi C., Olivotto I., Corti B., Potena L., Biagini E., Martin Suarez S., Rotellini M., Cecchi F., et al. Histopathological comparison of intramural coronary artery remodeling and myocardial fibrosis in obstructive versus end-stage hypertrophic cardiomyopathy. Int J Cardiol 2019; 291: 77–82. Doi: 10.1016/j.ijcard.2019.03.060.
[102] Kwon DH., Smedira NG., Rodriguez ER., Tan C., Setser R., Thamilarasan M., Lytle BW., Lever HM., Desai MY. Cardiac Magnetic Resonance Detection of Myocardial Scarring in Hypertrophic Cardiomyopathy. Correlation With Histopathology and Prevalence of Ventricular Tachycardia. J Am Coll Cardiol 2009; 54(3): 242–9. Doi: 10.1016/j.jacc.2009.04.026.
[103] Maron MS., Olivotto I., Maron BJ., Prasad SK., Cecchi F., Udelson JE., Camici PG. The Case for Myocardial Ischemia in Hypertrophic Cardiomyopathy. J Am Coll Cardiol 2009; 54(9): 866–75. Doi: 10.1016/j.jacc.2009.04.072.
[104] Mundhenke M., Schwartzkopff B., Strauer BE. Structural analysis of arteriolar and myocardial remodelling in the subendocardial region of patients with hypertensive heart disease and hypertrophic cardiomyopathy. Virchows Arch 1997; 431(4): 265–73. Doi: 10.1007/s004280050098.
[105] Nakamura T., Sakamoto K., Yamano T., Kikkawa M., Zen K., Hikosaka T., Kubota T., Azuma A., Nishimura T. Increased plasma brain natriuretic peptide level as a guide for silent myocardial ischemia in patients with non-obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 39(10): 1657–63. Doi: 10.1016/S0735-1097(02)01813-2.
[106] Raphael CE., Cooper R., Parker KH., Collinson J., Vassiliou V., Pennell DJ., de Silva R., Hsu LY., Greve AM., Nijjer S., et al. Mechanisms of Myocardial Ischemia in Hypertrophic Cardiomyopathy: Insights From Wave Intensity Analysis and Magnetic Resonance. J Am Coll Cardiol 2016; 68(15): 1651–60. Doi: 10.1016/j.jacc.2016.07.751.
[107] Sciagrà R., Calabretta R., Cipollini F., Passeri A., Castello A., Cecchi F., Olivotto I., Pupi A. Myocardial blood flow and left ventricular functional reserve in hypertrophic cardiomyopathy: a 13NH3 gated PET study. Eur J Nucl Med Mol Imaging 2017; 44(5): 866–75. Doi: 10.1007/s00259-016-3603-2.
[108] Shin YJ., Lee JH., Yoo JY., Kim JA., Jeon Y., Yoon YE., Chun EJ. Clinical significance of evaluating coronary atherosclerosis in adult patients with hypertrophic cardiomyopathy who have chest pain. Eur Radiol 2019; 29(9): 4593–602. Doi: 10.1007/s00330-018-5951-8.
[109] Liu W., Sun D., Yang J. Diastolic Dysfunction of Hypertrophic Cardiomyopathy Genotype-Positive Subjects Without Hypertrophy Is Detected by Tissue Doppler Imaging: A Systematic Review and Meta-analysis: A. J Ultrasound Med 2017; 36(10): 2093–103. Doi: 10.1002/jum.14250.
[110] Covella M., Rowin EJ., Hill NS., Preston IR., Milan A., Opotowsky AR., Maron BJ., Maron MS., Maron BA. Mechanism of Progressive Heart Failure and Significance of Pulmonary Hypertension in Obstructive Hypertrophic Cardiomyopathy. Circ Hear Fail 2017; 10(4): e003689. Doi: 10.1161/CIRCHEARTFAILURE.116.003689.
[111] Germans T., Rüssel IK., Götte MJ., Spreeuwenberg MD., Doevendans PA., Pinto YM., Van Der Geest RJ., Van Der Velden J., Wilde AA., Van Rossum AC. How do hypertrophic cardiomyopathy mutations affect myocardial function in carriers with normal wall thickness? Assessment with cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2010; 12(1): 13. Doi: 10.1186/1532-429X-12-13.
[112] Huang X., Yue Y., Wang Y., Deng Y., Liu L., Di Y., Sun S., Chen D., Fan L., Cao J. Assessment of left ventricular systolic and diastolic abnormalities in patients with hypertrophic cardiomyopathy using real-time three-dimensional echocardiography and two-dimensional speckle tracking imaging. Cardiovasc Ultrasound 2018; 16(1): 23. Doi: 10.1186/s12947-018-0142-y.
[113] Бокерия ЛА., Борисов КВ., Синев АФ. Улучшение диастолической функции левого и правого желудочков сердца после хирургической коррекции гипертрофической обструктивной кардиомиопатии при помощи оригинального способа. Грудная и Сердечно-Сосудистая Хирургия 1999; 4: 4–10.
[114] Bravo PE., Luo HC., Pozios I., Zimmerman SL., Corona-Villalobos CP., Sorensen L., Kamel IR., Bluemke DA., Wahl RL., Abraham MR., et al. Late gadolinium enhancement confined to the right ventricular insertion points in hypertrophic cardiomyopathy: An intermediate stage phenotype? Eur Heart J Cardiovasc Imaging 2016; 17(3): 293–300. Doi: 10.1093/ehjci/jev154.
[115] Fernández A., Vigliano CA., Casabé JH., Diez M., Favaloro LE., Guevara E., Favaloro RR., Laguens RP. Comparison of prevalence, clinical course, and pathological findings of left ventricular systolic impairment versus normal systolic function in patients with hypertrophic cardiomyopathy. Am J Cardiol 2011; 108(4): 548–55. Doi: 10.1016/j.amjcard.2011.03.083.
[116] Hiemstra YL., Debonnaire P., van Zwet EW., Bootsma M., Schalij MJ., Bax JJ., Delgado V., Marsan NA. Development of and Progression of Overt Heart Failure in Nonobstructive Hypertrophic Cardiomyopathy. Am J Cardiol 2018; 122(4): 656–62. Doi: 10.1016/j.amjcard.2018.04.038.
[117] Horimoto M., Yokota K., Inoue H., Takenaka T., Doi H., Ohno T., Sekiguchi M. Development of obstructive hypertrophic cardiomyopathy from nonobstructive hypertrophic cardiomyopathy. Am J Cardiol 1998; 82(3): 403–5. Doi: 10.1016/S0002-9149(98)00337-3.
[118] Melacini P., Basso C., Angelini A., Calore C., Bobbo F., Tokajuk B., Bellini N., Smaniotto G., Zucchetto M., Iliceto S., et al. Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy. Eur Heart J 2010; 31(17): 2111–23. Doi: 10.1093/eurheartj/ehq136.
[119] Maron MS., Hauser TH., Dubrow E., Horst TA., Kissinger K V., Udelson JE., Manning WJ. Right Ventricular Involvement in Hypertrophic Cardiomyopathy. Am J Cardiol 2007; 100(8): 1293–8. Doi: 10.1016/j.amjcard.2007.05.061.
[120] Li M., Zhang L., Zhang Z., Wang S., Dong N., Wang G., Xie M. Isolated Severe Right Ventricular Hypertrophic Cardiomyopathy. Ann Thorac Surg 2019; 107(1): e23–5. Doi: 10.1016/J.ATHORACSUR.2018.05.061.
[121] Falcone DM., Moore D., Lambert EC. Idiopathic hypertrophic cardiomyopathy involving the right ventricle. Am J Cardiol 1967; 19(5): 735–40. Doi: 10.1016/0002-9149(67)90480-8.
[122] Shimizu M., Kawai H., Yokota Y., Yokoyama M. Echocardiographic assessment of right ventricular obstruction in hypertrophic cardiomyopathy. Circ J 2003; 67(10): 855–60. Doi: 10.1253/circj.67.855.
[123] Бокерия ЛА., Борисов КВ., Синев А., Савченко ЕД., Антоненко ДВ., Юрпольская ЛФ., Соболева HН., Елисеев HН. Результаты медикаментозного и хирургического лечения гипертрофической кардиомиопатии с обструкцией выводных отделов левого и правого желудочков сердца. Грудная и Сердечно-Сосудистая Хирургия 2004; (2): 4–9.
[124] Pagourelias ED., Efthimiadis GK., Parcharidou DG., Gossios TD., Kamperidis V., Karoulas T., Karvounis H., Styliadis IH. Prognostic Value of Right Ventricular Diastolic Function Indices in Hypertrophic Cardiomyopathy. Eur J Echocardiogr 2011; 12(11): 809–17. Doi: 10.1093/EJECHOCARD/JER126.
[125] Shah JP., Yang Y., Chen S., Hagar A., Pu XB., Xia T., Ou Y., Chen M., Chen Y. Prevalence and Prognostic Significance of Right Ventricular Dysfunction in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol 2018; 122(11): 1932–8. Doi: 10.1016/j.amjcard.2018.08.043.
[126] Sheppard MN., Westaby J., Zullo E., Fernandez BVE., Cox S., Cox A. Sudden arrhythmic death and cardiomyopathy are important causes of sudden cardiac death in the UK: results from a national coronial autopsy database. Histopathology 2023; 82(7): 1056–66. Doi: 10.1111/HIS.14889.
[127] Кактурский Л. Внезапная смерть (клиническая морфология). Москва; 2000.
[128] Ревишвили АШ., Шляхто ЕВ., Попов СВ., Покушалов ЕА., Школьникова МА., Сулимов ВА., Голицын СП., Егоров ДФ., Бойцов СА., Давтян КВ., et al. Клинические рекомендации по проведению электрофизиологических исследований, катетерной абляции и применению имплантируемых антиаритмических устройств. Москва; 2017.
[129] Adabag AS., Casey SA., Kuskowski MA., Zenovich AG., Maron BJ. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 45(5): 697–704. Doi: 10.1016/j.jacc.2004.11.043.
[130] Czosek RJ., Jefferies JL., Khoury PR., Anderson JB., Wilmot I., Knilans TK., Spar DS. Arrhythmic Burden and Ambulatory Monitoring of Pediatric Patients with Cardiomyopathy. Pacing Clin Electrophysiol 2016; 39(5): 443–51. Doi: 10.1111/pace.12835.
[131] Desai MY., Mentias A. Risk stratification in hypertrophic cardiomyopathy. Aging (Albany NY) 2019; 11(6): 1617–8. Doi: 10.18632/aging.101895.
[132] Elliott PM., Poloniecki J., Dickie S., Sharma S., Monserrat L., Varnava A., Mahon NG., McKenna WJ. Sudden death in hypertrophic cardiomyopathy: Identification of high risk patients. J Am Coll Cardiol 2000; 36(7): 2212–8. Doi: 10.1016/S0735-1097(00)01003-2.
[133] Goyal V., Jassal DS., Dhalla NS. Pathophysiology and prevention of sudden cardiac death. Can J Physiol Pharmacol 2015; 94(3): 237–44. Doi: 10.1139/cjpp-2015-0366.
[134] Marrakchi S., Kammoun I., Bennour E., Laroussi L., Kachboura S. Risk stratification in hypertrophic cardiomyopathy. Herz 2020; 45(1): 50–64. Doi: 10.1007/s00059-018-4700-8.
[135] Weissler-Snir A., Adler A., Williams L., Gruner C., Rakowski H. Prevention of Sudden Death in Hypertrophic Cardiomyopathy: Bridging the Gaps in Knowledge. Eur Hear J 2017; 38(22): 1728–37.
[136] Weissler-Snir A., Chan RH., Adler A., Care M., Chauhan V., Gollob MH., Ziv-Baran T., Fourey D., Hindieh W., Rakowski H., et al. Usefulness of 14-Day Holter for Detection of Nonsustained Ventricular Tachycardia in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol 2016; 118(8): 1258–63. Doi: 10.1016/j.amjcard.2016.07.043.
[137] Zipes DP., Camm AJ., Borggrefe M., Buxton AE., Chaitman B., Fromer M., Gregoratos G., Klein G., Moss AJ., Myerburg RJ., et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Europace 2006; 8(9): 746–837. Doi: 10.1093/europace/eul108.
[138] Goff ZD., Calkins H. Sudden death related cardiomyopathies - Hypertrophic cardiomyopathy. Prog Cardiovasc Dis 2019; 62(3): 212–6. Doi: 10.1016/j.pcad.2019.04.001.
[139] Zeppenfeld K., Tfelt-Hansen J., De Riva M., Winkel BG., Behr ER., Blom NA., Charron P., Corrado D., Dagres N., De Chillou C., et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2022; 43(40): 3997–4126. Doi: 10.1093/EURHEARTJ/EHAC262.
[140] Bois JP., Adams JC., Kumar G., Ommen SR., Nishimura RA., Klarich KW. Relation between temperature extremes and symptom exacerbation in patients with hypertrophic cardiomyopathy. Am J Cardiol 2016; 117(6): 961–5. Doi: 10.1016/j.amjcard.2015.12.046.
[141] Haghjoo M., Faghfurian B., Taherpour M., Fazelifar AF., Mohammadzadeh S., Alizadeh A., Sadr-Ameli MA. Predictors of syncope in patients with hypertrophic cardiomyopathy. PACE - Pacing Clin Electrophysiol 2009; 32(5): 642–7. Doi: 10.1111/j.1540-8159.2009.02338.x.
[142] Seggewiß H., Koljaja-Batzner A., Seggewiß K., Meesmann M. Syncope in hypertrophic (obstructive) cardiomyopathy. Herzschrittmachertherapie Und Elektrophysiologie 2018; 29(2): 178–82. Doi: 10.1007/s00399-018-0567-x.
[143] Williams L., Frenneaux M. Syncope in Hypertrophic Cardiomyopathy: Mechanisms and Consequences for Treatment. Europace 2007; 9(9): 817–22.
[144] Farhad H., Seidelmann SB., Vigneault D., Abbasi SA., Yang E., Day SM., Colan SD., Russell MW., Towbin J., Sherrid M V., et al. Left Atrial structure and function in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. J Cardiovasc Magn Reson 2017; 19(1): 107. Doi: 10.1186/s12968-017-0420-0.
[145] Burstein B., Nattel S. Atrial Fibrosis: Mechanisms and Clinical Relevance in Atrial Fibrillation. J Am Coll Cardiol 2008; 51(8): 802–9. Doi: 10.1016/j.jacc.2007.09.064.
[146] Philipson DJ., Rader F., Siegel RJ. Risk factors for atrial fibrillation in hypertrophic cardiomyopathy. Eur J Prev Cardiol 2019: doi: 10.1177/2047487319828474. Online ahead of pri. Doi: 10.1177/2047487319828474.
[147] Kirchhof P., Benussi S., Kotecha D., Ahlsson A., Atar D., Casadei B., Castella M., Diener H-C., Heidbuchel H., Hendriks J., et al. 2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS. Eur Heart J 2016; 37: 2893–962.
[148] Hindricks G., Potpara T., Dagres N., Bax JJ., Boriani G., Dan GA., Fauchier L., Kalman JM., Lane DA., Lettino M., et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the Europea. Eur Heart J 2021; 42(5): 373–498. Doi: 10.1093/EURHEARTJ/EHAA612.
[149] Maron BJ., Rowin EJ., Udelson JE., Maron MS. Clinical Spectrum and Management of Heart Failure in Hypertrophic Cardiomyopathy. JACC Hear Fail 2018; 6(5): 353–63. Doi: 10.1016/j.jchf.2017.09.011.
[150] Seferović PM., Polovina M., Bauersachs J., Arad M., Gal T Ben., Lund LH., Felix SB., Arbustini E., Caforio ALP., Farmakis D., et al. Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2019; 21(5): 553–76. Doi: 10.1002/ejhf.1461.
[151] Garg L., Gupta M., Sabzwari SRA., Agrawal S., Agarwal M., Nazir T., Gordon J., Bozorgnia B., Martinez MW. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management. Heart Fail Rev 2019; 24(2): 189–97. Doi: 10.1007/s10741-018-9752-6.
[152] Arakelyan MG., Bockeria LA., Vasilieva EY., Golitsyn SP., Golukhova EZ., Gorev M V., Davtyan K V., Drapkina OM., Kropacheva ES., Kuchinskaya EA., et al. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. Российский Кардиологический Журнал 2021; 26(7): 4594. Doi: 10.15829/1560-4071-2021-4594.
[153] Donnellan E., Wazni OM., Hanna M., Elshazly MB., Puri R., Saliba W., Kanj M., Vakamudi S., Patel DR., Baranowski B., et al. Atrial Fibrillation in Transthyretin Cardiac Amyloidosis: Predictors, Prevalence, and Efficacy of Rhythm Control Strategies. JACC Clin Electrophysiol 2020; 6(9): 1118–27. Doi: 10.1016/J.JACEP.2020.04.019.
[154] Marstrand P., Han L., Day SM., Olivotto I., Ashley EA., Michels M., Pereira AC., Wittekind SG., Helms A., Saberi S., et al. Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Insights From the SHaRe Registry. Circulation 2020; 141(17): 1371–83. Doi: 10.1161/CIRCULATIONAHA.119.044366.
[155] Tereshchenko SN., Galyavich AS., Uskach TM., Ageev FT., Arutyunov GP., Begrambekova YL., Belenkov YN., Boytsov SA., Vasyuk YA., Garganeeva AA., et al. 2020 Clinical practice guidelines for Chronic heart failure. Russ J Cardiol 2020; 25(11): 4083. Doi: 10.15829/1560-4071-2020-4083.
[156] McDonagh TA., Metra M., Adamo M., Baumbach A., Böhm M., Burri H., Čelutkiene J., Chioncel O., Cleland JGF., Coats AJS., et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42(36): 3599–726. Doi: 10.1093/EURHEARTJ/EHAB368.
[157] Heidenreich PA., Bozkurt B., Aguilar D., Allen LA., Byun JJ., Colvin MM., Deswal A., Drazner MH., Dunlay SM., Evers LR., et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2022; 79(17): e263–421. Doi: 10.1016/j.jacc.2021.12.012.
[158] Pálinkás ED., Re F., Peteiro J., Tesic M., Pálinkás A., Torres MAR., Dikic AD., Beleslin B., Van De Heyning CM., D’Alfonso MG., et al. Pulmonary congestion during Exercise stress Echocardiography in Hypertrophic Cardiomyopathy. Int J Cardiovasc Imaging 2022; 38(12): 2593–604. Doi: 10.1007/S10554-022-02620-0.
[159] Maron MS., Finley JJ., Bos JM., Hauser TH., Manning WJ., Haas TS., Lesser JR., Udelson JE., Ackerman MJ., Maron BJ. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation 2008; 118(15): 1541–9. Doi: 10.1161/CIRCULATIONAHA.108.781401.
[160] Towe EC., Bos JM., Ommen SR., Gersh BJ., Ackerman MJ. Genotype-Phenotype Correlations in Apical Variant Hypertrophic Cardiomyopathy. Congenit Heart Dis 2015; 10(3): E139–45. Doi: 10.1111/CHD.12242.
[161] Rowin EJ., Maron BJ., Haas TS., Garberich RF., Wang W., Link MS., Maron MS. Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm: Implications for Risk Stratification and Management. J Am Coll Cardiol 2017; 69(7): 761–73. Doi: 10.1016/J.JACC.2016.11.063.
[162] Yang K., Song YY., Chen XY., Wang JX., Li L., Yin G., Zheng YC., Wei MD., Lu MJ., Zhao SH. Apical hypertrophic cardiomyopathy with left ventricular apical aneurysm: prevalence, cardiac magnetic resonance characteristics, and prognosis. Eur Hear Journal Cardiovasc Imaging 2020; 21(12): 1341–50. Doi: 10.1093/EHJCI/JEAA246.
[163] Calabretta R., Kokomani A., Fumagalli C., Olivotto I., Camici PG., Hacker M., Sciagrà R. Evaluation of stress myocardial blood flow patterns in patients with apical hypertrophic cardiomyopathy. J Nucl Cardiol 2022; 29(4): 1946–51. Doi: 10.1007/S12350-022-02911-Y.
[164] Cui L., Suo Y., Zhao Y., Li G., Liu T. Mid-Ventricular Obstructive Hypertrophic Cardiomyopathy and Apical Aneurysm Mimicking Acute ST-Elevation Myocardial Infarction. Ann Noninvasive Electrocardiol 2016; 21(1): 98–101. Doi: 10.1111/ANEC.12284.
[165] Mörner S., Johansson B., Henein M. Arrhythmogenic left ventricular apical aneurysm in hypertrophic cardiomyopathy. Int J Cardiol 2011; 151(1): e8. Doi: 10.1016/J.IJCARD.2010.02.071.
[166] Dilaveris P., Aggeli C., Synetos A., Skiadas I., Antoniou CK., Tsiamis E., Gatzoulis K., Kallikazaros I., Tousoulis D. Sustained ventricular tachycardia as a first manifestation of hypertrophic cardiomyopathy with mid-ventricular obstruction and apical aneurysm in an elderly female patient. Ann Noninvasive Electrocardiol 2017; 22(3): e12422. Doi: 10.1111/ANEC.12422.
[167] Pérez-Riera AR., Barbosa-Barros R., de Lucca AA., Viana MJ., de Abreu LC. Mid-ventricular Hypertrophic Obstructive Cardiomyopathy with Apical Aneurysm Complicated with Syncope by Sustained Monomorphic Ventricular Tachycardia. Ann Noninvasive Electrocardiol 2016; 21(6): 618–21. Doi: 10.1111/ANEC.12377.
[168] Papanastasiou CA., Zegkos T., Karamitsos TD., Rowin EJ., Maron MS., Parcharidou D., Kokkinidis DG., Karvounis H., Rimoldi O., Maron BJ., et al. Prognostic role of left ventricular apical aneurysm in hypertrophic cardiomyopathy: A systematic review and meta-analysis. Int J Cardiol 2021; 332: 127–32. Doi: 10.1016/J.IJCARD.2021.03.056.
[169] Chang HC., Kuo L., Sung SH., Weng CY., Chen CK., Niu DM., Chen SA., Yu WC. Left Ventricular Apical Aneurysm in Fabry Disease: Implications for Clinical Significance and Risk Stratification. J Am Heart Assoc 2023; 12(1): e027041. Doi: 10.1161/JAHA.122.027041.
[170] Terai H., Shimizu M., Ino H., Yamaguchi M., Uchiyama K., Oe K., Nakajima K., Taki J., Kawano M., Mabuchi H. Changes in cardiac sympathetic nerve innervation and activity in pathophysiologic transition from typical to end-stage hypertrophic cardiomyopathy. J Nucl Med 2003; 44(10): 1612–7.
[171] Ciampi Q., Olivotto I., Peteiro J., D’alfonso MG., Mori F., Tassetti L., Milazzo A., Monserrat L., Fernandez X., Pálinkás A., et al. Prognostic Value of Reduced Heart Rate Reserve during Exercise in Hypertrophic Cardiomyopathy. J Clin Med 2021; 10(7): 1347. Doi: 10.3390/JCM10071347.
[172] Maron BA., Kleiner DE., Arons E., Wertheim BM., Sharma NS., Haley KJ., Samokhin AO., Rowin EJ., Maron MS., Rosing DR., et al. Evidence of Advanced Pulmonary Vascular Remodeling in Obstructive Hypertrophic Cardiomyopathy With Pulmonary Hypertension. Chest 2023; 163(3): 678–86. Doi: 10.1016/J.CHEST.2022.09.040.
[173] Re F., Halasz G., Moroni F., Beltrami M., Baratta P., Avella A., Zachara E., Olivotto I. Exercise-induced pulmonary hypertension in hypertrophic cardiomyopathy: a combined cardiopulmonary exercise test-echocardiographic study. Int J Cardiovasc Imaging 2022; 38(11): 2345–52. Doi: 10.1007/S10554-022-02671-3.
[174] Geske JB., Konecny T., Ommen SR., Nishimura RA., Sorajja P., Schaff H V., Ackerman MJ., Gersh BJ. Surgical myectomy improves pulmonary hypertension in obstructive hypertrophic cardiomyopathy. Eur Heart J 2014; 35(30): 2032–9. Doi: 10.1093/EURHEARTJ/EHT537.
[175] Maron BJ., Olivotto I., Spirito P., Casey SA., Bellone P., Gohman TE., Graham KJ., Burton DA., Cecchi F. Epidemiology of Hypertrophic Cardiomyopathy–Related Death. Circulation 2000; 102(8): 858–64. Doi: 10.1161/01.CIR.102.8.858.
[176] Semsarian C., Ingles J., Maron MS., Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol 2015; 65(12): 1249–54. Doi: 10.1016/j.jacc.2015.01.019.
[177] Maurer MS., Hanna M., Grogan M., Dispenzieri A., Witteles R., Drachman B., Judge DP., Lenihan DJ., Gottlieb SS., Shah SJ., et al. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol 2016; 68(2): 161–72. Doi: 10.1016/J.JACC.2016.03.596.
[178] Rigopoulos AG., Ali M., Abate E., Torky AR., Matiakis M., Mammadov M., Melnyk H., Vogt A., de Vecchis R., Bigalke B., et al. Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement. Heart Fail Rev 2019; 24(4): 521–33. Doi: 10.1007/S10741-019-09776-3.
[179] Amano Y., Kitamura M., Takayama M., Tachi M., Kumita S. MRI classification of asymmetric septal hypertrophic cardiomyopathy and its relation to the presence of risk factors. Int J Cardiovasc Imaging 2012; 28(8): 2019–25. Doi: 10.1007/s10554-012-0034-4.
[180] Geske JB., Ommen SR., Gersh BJ. Hypertrophic Cardiomyopathy: Clinical Update. JACC Hear Fail 2018; 6(5): 364–75. Doi: 10.1016/j.jchf.2018.02.010.
[181] Neubauer S., Kolm P., Ho CY., Kwong RY., Desai MY., Dolman SF., Appelbaum E., Desvigne-Nickens P., DiMarco JP., Friedrich MG., et al. Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry. J Am Coll Cardiol 2019; 74(19): 2333–45. Doi: 10.1016/J.JACC.2019.08.1057.
[182] Игнатенко ГА., Тарадин ГГ., Куглер ТЕ. Особенности гипертрофии левого желудочка и характеристика фенотипических вариантов у больных гипертрофической кардиомиопатией. Архивъ Внутренней Медицины 2023; 13(4): 282–93. Doi: 10.20514/2226-6704-2023-13-4-282-293.
[183] Rapezzi C., Arbustini E., Caforio ALP., Charron P., Gimeno-Blanes J., Heliö T., Linhart A., Mogensen J., Pinto Y., Ristic A., et al. Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. Eur Hear J 2013; 34: 1448–58.
[184] Gudkova A., Kostareva A., Sjoberg G., Smolina N., Turalchuk M., Kuznetsova I., Rybakova M., Edstrom L., Shlyakhto E., Sejersen T. Diagnostic challenge in desmin cardiomyopathy with transformation of clinical phenotypes. Pediatr Cardiol 2013; 34(2): 467–70. Doi: 10.1007/s00246-012-0312-x.
[185] Olivotto I., Cecchi F., Poggesi C., Yacoub MH. Patterns of disease progression in hypertrophic cardiomyopathy an individualized approach to clinical staging. Circ Hear Fail 2012; 5(4): 535–46. Doi: 10.1161/CIRCHEARTFAILURE.112.967026.
[186] Argirò A., Zampieri M., Marchi A., Cappelli F., Del Franco A., Mazzoni C., Cecchi F., Olivotto I. Stage-specific therapy for hypertrophic cardiomyopathy. Eur Heart J Suppl 2023; 25(Suppl C): C155–61. Doi: 10.1093/EURHEARTJSUPP/SUAD042.
[187] Rowin EJ., Maron MS., Chan RH., Hausvater A., Wang W., Rastegar H., Maron BJ. Interaction of Adverse Disease Related Pathways in Hypertrophic Cardiomyopathy. Am J Cardiol 2017; 120(12): 2256–64. Doi: 10.1016/j.amjcard.2017.08.048.
[188] Габрусенко СА., Сафрыгина ЮВ., Овчинников АГ., Масенко ВП., Наумов ВГ., Агеев ФТ., Беленков ЮН. Клинико-гемодинамический статус и сердечные натрийуретические пептиды в плазме больных гипертрофической кардиомиопатией. Кардиологический Вестник (Бюллетень РКНПК) 2006; 1(2): 25–31.
[189] Дземешкевич СЛ., Фролова ЮВ., Ким СЮ., Федоров ДН., Заклязьминская ЕВ., Федулова СВ., Шапиева АН., Маликова МС., Луговой АН. Анатомические и морфологические признаки диффузно-генерализованной формы гипертрофической кардиомиопатии. Российский Кардиологический Журнал 2015; 5(121): 58–63.
[190] Стрельцова АА., Гудкова АЯ., Костарева АА. Фибрилляция предсердий при гипертрофической кардиомиопатии: современные аспекты эпидемиологии, факторов риска, патогенеза и фармакотерапии. Cons Medicum 2018; 20(5): 34–9.
[191] Стрельцова АА., Гудкова АЯ., Полякова АА., Пыко СА., Костарева АА. Полиморфный вариант rs1739843 гена белка теплового шока 7 (HSPB7) и его связь с вариантами клинического течения и исходами у пациентов с гипертрофической кардиомиопатией (результаты 10-летнего наблюдения). Российский Кардиологический Журнал 2019; (10): 7–15.
[192] Harris KM., Spirito P., Maron MS., Zenovich AG., Formisano F., Lesser JR., Mackey-Bojack S., Manning WJ., Udelson JE., Maron BJ. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 2006; 114(3): 216–25. Doi: 10.1161/CIRCULATIONAHA.105.583500.
[193] Bos JM., Ommen SR., Ackerman MJ. Genetics of hypertrophic cardiomyopathy: one, two, or more diseases? Curr Opin Cardiol 2007; 22(3): 193–9. Doi: 10.1097/HCO.0b013e3280e1cc7f.
[194] Lancellotti P., Pellikka PA., Budts W., Chaudhry FA., Donal E., Dulgheru R., Edvardsen T., Garbi M., Ha JW., Kane GC., et al. The Clinical Use of Stress Echocardiography in Non-Ischaemic Heart Disease: Recommendations from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr 2017; 30(2): 101–38. Doi: 10.1016/j.echo.2016.10.016.
[195] Parato VM., Antoncecchi V., Sozzi F., Marazia S., Zito A., Maiello M., Palmiero P. Echocardiographic diagnosis of the different phenotypes of hypertrophic cardiomyopathy. Cardiovasc Ultrasound 2016; 14(1): 30. Doi: 10.1186/s12947-016-0072-5.
[196] Ponikowski P., Voors AA., Anker SD., Bueno H., Cleland JGF., Coats AJS., Falk V., González-Juanatey JR., Harjola VP., Jankowska EA., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution . Eur J Heart Fail 2016; 18(8): 891–975. Doi: 10.1002/ejhf.592.
[197] Maron BJ., McKenna WJ., Danielson GK., Kappenberger LJ., Kuhn HJ., Seidman CE., Shah PM., Spencer WH., Spirito P., Ten Cate FJ., et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European S. Eur Heart J 2003; 24(21): 1965–91. Doi: 10.1016/S0195-668X(03)00479-2.
[198] Merlo M., Pagura L., Porcari A., Cameli M., Vergaro G., Musumeci B., Biagini E., Canepa M., Crotti L., Imazio M., et al. Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC-TIVE study, an Italian nationwide survey. Eur J Heart Fail 2022; 24(8): 1377–86. Doi: 10.1002/EJHF.2504.
[199] Cantwell JD. Preparticipation physical evaluation: Getting to the heart of the matter. Med Sci Sports Exerc 1998; 30(10): 341–4. Doi: 10.1097/00005768-199810001-00001.
[200] Efthimiadis GK., Parcharidou D., Pagourelias ED., Meditskou S., Spanos G., Hadjimiltiades S., Pliakos C., Gavrielides S., Karvounis H., Styliadis IH., et al. Prevalence and Clinical Outcomes of Incidentally Diagnosed Hypertrophic Cardiomyopathy. Am J Cardiol 2010; 105(10): 1445–50. Doi: 10.1016/j.amjcard.2009.12.066.
[201] Harmon KG., Zigman M., Drezner JA. The effectiveness of screening history, physical exam, and ECG to detect potentially lethal cardiac disorders in athletes: A systematic review/meta-analysis. J Electrocardiol 2015; 48(3): 329–38. Doi: 10.1016/j.jelectrocard.2015.02.001.
[202] Raviele A., Giada F., Bergfeldt L., Blanc JJ., Blomstrom-Lundqvist C., Mont L., Morgan JM., Raatikainen MJP., Steinbeck G., Viskin S., et al. Management of Patients With Palpitations: A Position Paper From the European Heart Rhythm Association. Europace 2011; 13(7): 920–34.
[203] Attenhofer Jost CH., Turina J., Mayer K., Seifert B., Amann FW., Buechi M., Facchini M., Brunner-La Rocca HP., Jenni R. Echocardiography in the evaluation of systolic murmurs of unknown cause. Am J Med 2000; 108(8): 614–20. Doi: 10.1016/S0002-9343(00)00361-2.
[204] Barrett MJ., Ayub B., Martinez MW. Cardiac auscultation in sports medicine: Strategies to improve clinical care. Curr Sports Med Rep 2012; 11(2): 78–84. Doi: 10.1249/JSR.0b013e318249c0ff.
[205] Nagueh SF., Phelan D., Abraham T., Armour A., Desai MY., Dragulescu A., Gilliland Y., Lester SJ., Maldonado Y., Mohiddin S., et al. Recommendations for Multimodality Cardiovascular Imaging of Patients with Hypertrophic Cardiomyopathy: An Update from the American Society of Echocardiography, in Collaboration with the American Society of Nuclear Cardiology, the Society for Cardiovascula. J Am Soc Echocardiogr 2022; 35(6): 533–69. Doi: 10.1016/J.ECHO.2022.03.012.
[206] Barcia G., Rachid M., Magen M., Assouline Z., Koenig M., Funalot B., Barnerias C., Rötig A., Munnich A., Bonnefont JP., et al. Pitfalls in molecular diagnosis of Friedreich ataxia. Eur J Med Genet 2018; 61(8): 455–8. Doi: 10.1016/j.ejmg.2018.03.004.
[207] Monserrat L., Gimeno-Blanes JR., Marín F., Hermida-Prieto M., García-Honrubia A., Pérez I., Fernández X., de Nicolas R., de la Morena G., Payá E., et al. Prevalence of Fabry Disease in a Cohort of 508 Unrelated Patients With Hypertrophic Cardiomyopathy. J Am Coll Cardiol 2007; 50(25): 2399–403. Doi: 10.1016/j.jacc.2007.06.062.
[208] Rapezzi C., Quarta CC., Obici L., Perfetto F., Longhi S., Salvi F., Biagini E., Lorenzini M., Grigioni F., Leone O., et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Hear J 2013; 34(7): 520–8.
[209] Sarkozy A., Digilio MC., Dallapiccola B. Leopard syndrome. Orphanet J Rare Dis 2008; 3(1): Article number: 13. Doi: 10.1186/1750-1172-3-13.
[210] Scaglia F., Towbin JA., Craigen WJ., Belmont JW., Smith EOB., Neish SR., Ware SM., Hunter J V., Fernbach SD., Vladutiu GD., et al. Clinical Spectrum, Morbidity, and Mortality in 113 Pediatric Patients with Mitochondrial Disease. Pediatrics 2004; 114(4): 925–31. Doi: 10.1542/peds.2004-0718.
[211] Yang Z., Vatta M. Danon disease as a cause of autophagic vacuolar myopathy. Congenit Heart Dis 2007; 2(6): 404–9. Doi: 10.1111/j.1747-0803.2007.00132.x.
[212] Yang Z., McMahon CJ., Smith LR., Bersola J., Adesina AM., Breinholt JP., Kearney DL., Dreyer WJ., Denfield SW., Price JF., et al. Danon Disease as an Underrecognized Cause of Hypertrophic Cardiomyopathy in Children. Circulation 2005; 112(11): 1612–7. Doi: 10.1161/CIRCULATIONAHA.105.546481.
[213] Pagourelias ED., Efthimiadis GK., Kouidi E., Zorou P., Giannoglou G., Deligiannis A., Athyros VG., Karagiannis A., Geleris P. Efficacy of various “classic” echocardiographic and laboratory indices in distinguishing the “gray zone” between athlete’s heart and hypertrophic cardiomyopathy: A pilot study. Echocardiography 2013; 30(2): 131–9. Doi: 10.1111/echo.12014.
[214] Grogan M., Scott CG., Kyle RA., Zeldenrust SR., Gertz MA., Lin G., Klarich KW., Miller WL., Maleszewski JJ., Dispenzieri A. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. J Am Coll Cardiol 2016; 68(10): 1014–20. Doi: 10.1016/J.JACC.2016.06.033.
[215] Vergaro G., Castiglione V., Aimo A., Prontera C., Masotti S., Musetti V., Nicol M., Cohen Solal A., Logeart D., Georgiopoulos G., et al. N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis. Eur J Heart Fail 2023; 25(3): 1014–20. Doi: 10.1002/EJHF.2769.
[216] Witteles RM., Bokhari S., Damy T., Elliott PM., Falk RH., Fine NM., Gospodinova M., Obici L., Rapezzi C., Garcia-Pavia P. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. JACC Heart Fail 2019; 7(8): 709–16. Doi: 10.1016/J.JCHF.2019.04.010.
[217] Damy T., Costes B., Hagège AA., Donal E., Eicher JC., Slama M., Guellich A., Rappeneau S., Gueffet JP., Logeart D., et al. Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. Eur Heart J 2016; 37(23): 1826–34. Doi: 10.1093/EURHEARTJ/EHV583.
[218] Maurizi N., Rella V., Fumagalli C., Salerno S., Castelletti S., Dagradi F., Torchio M., Marceca A., Meda M., Gasparini M., et al. Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy. Int J Cardiol 2020; 300: 191–5. Doi: 10.1016/J.IJCARD.2019.07.051.
[219] Профстандарт 02.054 | Врач-генетик | Профессиональные стандарты 2023. https://classinform.ru/profstandarty/02.054-vrach-genetik.html. [accessed May 25, 2023].
[220] Richards S., Aziz N., Bale S., Bick D., Das S., Gastier-Foster J., Grody WW., Hegde M., Lyon E., Spector E., et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17(5): 405–24. Doi: 10.1038/gim.2015.30.
[221] Ackerman MJ., Priori SG., Willems S., Berul C., Brugada R., Calkins H., Camm AJ., Ellinor PT., Gollob M., Hamilton R., et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Hear Rhythm 2011; 8(8): 1308–39. Doi: 10.1016/J.HRTHM.2011.05.020.
[222] Hershberger RE., Givertz MM., Ho CY., Judge DP., Kantor PF., McBride KL., Morales A., Taylor MRG., Vatta M., Ware SM. Genetic Evaluation of Cardiomyopathy—A Heart Failure Society of America Practice Guideline. J Card Fail 2018; 24(5): 281–302. Doi: 10.1016/j.cardfail.2018.03.004.
[223] Wilde AAM., Semsarian C., Márquez MF., Sepehri Shamloo A., Ackerman MJ., Ashley EA., Sternick Eduardo B., Barajas-Martinez H., Behr ER., Bezzina CR., et al. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases. Europace 2022; 24(8): 1307–67. Doi: 10.1002/joa3.12717.
[224] Габрусенко СА., Селезнёв ДМ., Наумов ВГ. Генетические аспекты гипертрофической кардиомиопатии (обзор литературы). Практикующий Врач 2000; 18(2): 2–5.
[225] Селезнев ДМ., Габрусенко СА., Парфенова ЕВ., Наумов ВГ., Стамбольский ДВ., Ткачук ВА. Роль мутаций в гене тяжелой цепи сердечного бета-миозина в российской популяции больных с гипертрофической кардиомиопатией. Кардиология 2005; 45(4): 15–20.
[226] Рыжкова ОП., Кардымон ОЛ., Прохорчук ЕБ., Коновалов ФА., Масленников АБ., Степанов ВА. Руководство по интерпретации данных последовательности ДНК человека, полученных методами массового параллельного секвенирования (MPS) (редакция 2018, версия 2). Медицинская Генетика 2019; 18(2): 3–23.
[227] Charron P., Forissier JF., Amara ME., Dubourg O., Desnos M., Bouhour JB., Isnard R., Hagege A., Bénaïche A., Richard P., et al. Accuracy of European diagnostic criteria for familial hypertrophic cardiomyopathy in a genotyped population. Int J Cardiol 2003; 90(1): 33–8. Doi: 10.1016/S0167-5273(02)00534-X.
[228] Дроздов ДВ., Макаров ЛМ., Баркан ВС., Газашвили ТМ., Ефимова ВП., Жук МЮ., Иртюга ОБ., Калинин ЛА., Ковалёв ИА., Комолятова ВН., et al. Регистрация электрокардиограммы покоя в 12 общепринятых отведениях взрослым и детям 2023. Методические рекомендации. Российский Кардиологический Журнал 2023; 28(10): 5631. Doi: https://doi.org/10.15829/1560-4071-2023-5631.
[229] Jalanko M., Heliö T., Mustonen P., Kokkonen J., Huhtala H., Laine M., Jääskeläinen P., Tarkiainen M., Lauerma K., Sipola P., et al. Novel electrocardiographic features in carriers of hypertrophic cardiomyopathy causing sarcomeric mutations. J Electrocardiol 2018; 51(6): 983–9. Doi: 10.1016/J.JELECTROCARD.2018.07.009.
[230] Lakdawala NK., Thune JJ., Maron BJ., Cirino AL., Havndrup O., Bundgaard H., Christiansen M., Carlsen CM., Dorval JF., Kwong RY., et al. Electrocardiographic features of sarcomere mutation carriers with and without clinically overt hypertrophic cardiomyopathy. Am J Cardiol 2011; 108(11): 1606–13. Doi: 10.1016/J.AMJCARD.2011.07.019.
[231] Finocchiaro G., Sheikh N., Biagini E., Papadakis M., Maurizi N., Sinagra G., Pelliccia A., Rapezzi C., Sharma S., Olivotto I. The electrocardiogram in the diagnosis and management of patients with hypertrophic cardiomyopathy. Hear Rhythm 2020; 17(1): 142–51. Doi: 10.1016/J.HRTHM.2019.07.019.
[232] Bernardini A., Crotti L., Olivotto I., Cecchi F. Diagnostic and prognostic electrocardiographic features in patients with hypertrophic cardiomyopathy. Eur Heart J Suppl 2023; 25(Suppl C): C173–8. Doi: 10.1093/EURHEARTJSUPP/SUAD074.
[233] McLeod CJ., Ackerman MJ., Nishimura RA., Tajik AJ., Gersh BJ., Ommen SR. Outcome of Patients With Hypertrophic Cardiomyopathy and a Normal Electrocardiogram. J Am Coll Cardiol 2009; 54(3): 229–33. Doi: 10.1016/j.jacc.2009.02.071.
[234] Arima N., Ochi Y., Takahashi M., Moriki T., Noguchi T., Kubo T., Yamasaki N., Kitaoka H. Transient decrease in the depth of the negative T wave in apical hypertrophic cardiomyopathy is a sign of left anterior descending artery stenosis: a case series. Eur Hear Journal Case Reports 2023; 7(1): ytad034. Doi: 10.1093/EHJCR/YTAD034.
[235] Delcrè SDL., Di Donna P., Leuzzi S., Miceli S., Bisi M., Scaglione M., Caponi D., Conte MR., Cecchi F., Olivotto I., et al. Relationship of ECG findings to phenotypic expression in patients with hypertrophic cardiomyopathy: a cardiac magnetic resonance study. Int J Cardiol 2013; 167(3): 1038–45. Doi: 10.1016/J.IJCARD.2012.03.074.
[236] Biagini E., Pazzi C., Olivotto I., Musumeci B., Limongelli G., Boriani G., Pacileo G., Mastromarino V., Bacchi Reggiani ML., Lorenzini M., et al. Usefulness of Electrocardiographic Patterns at Presentation to Predict Long-term Risk of Cardiac Death in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol 2016; 118(3): 432–9. Doi: 10.1016/J.AMJCARD.2016.05.023.
[237] Bi X., Yang C., Song Y., Yuan J., Cui J., Hu F., Qiao S. Quantitative fragmented QRS has a good diagnostic value on myocardial fibrosis in hypertrophic obstructive cardiomyopathy based on clinical-pathological study. BMC Cardiovasc Disord 2020; 20(1): 298. Doi: 10.1186/S12872-020-01590-2.
[238] Kang KW., Janardhan AH., Jung KT., Lee HS., Lee MH., Hwang HJ. Fragmented QRS as a candidate marker for high-risk assessment in hypertrophic cardiomyopathy. Hear Rhythm 2014; 11(8): 1433–40. Doi: 10.1016/J.HRTHM.2014.05.002.
[239] Fananapazir L., Tracy CM., Leon MB., Winkler JB., Cannon RO., Bonow RO., Maron BJ., Epstein SE. Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy. A consecutive analysis in 155 patients. Circulation 1989; 80(5): 1259–68. Doi: 10.1161/01.CIR.80.5.1259.
[240] Kelly BS., Mattu A., Brady WJ. Hypertrophic cardiomyopathy: electrocardiographic manifestations and other important considerations for the emergency physician. Am J Emerg Med 2007; 25(1): 72–9. Doi: 10.1016/j.ajem.2006.04.017.
[241] Wilke I., Witzel K., MÜnch J., Pecha S., Blankenberg S., Reichenspurner H., Willems S., Patten M., Aydin A. High Incidence of De Novo and Subclinical Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy and Cardiac Rhythm Management Device. J Cardiovasc Electrophysiol 2016; 27(7): 779–84. Doi: 10.1111/jce.12982.
[242] Хирманов ВН., Трешкур ТВ., Тюрина ТВ., Юзвинкевич СА., Порядина ИИ. Электрокардиографические методы в диагностике, выборе метода и тактики лечения гипертрофической кардиомиопатии. Prog Biomed Res 1997; 2(1): 7–22.
[243] O’Mahony C., Jichi F., Pavlou M., Monserrat L., Anastasakis A., Rapezzi C., Biagini E., Gimeno JR., Limongelli G., Mckenna WJ., et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). Eur Hear J 2014; 35(30): 2010–20. Doi: 10.1093/eurheartj/eht439.
[244] Wasfy MM., Weiner RB. Differentiating the athlete’s heart from hypertrophic cardiomyopathy. Curr Opin Cardiol 2015: 500–5. Doi: 10.1097/HCO.0000000000000203.
[245] Weigner MJ., Caulfield TA., Danias PG., Silverman DI., Manning WJ. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med 1997; 126(8): 615–20. Doi: 10.7326/0003-4819-126-8-199704150-00005.
[246] Guttmann OP., Rahman MS., O’Mahony C., Anastasakis A., Elliott PM. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: Systematic review. Heart 2014; 100(6): 465–72. Doi: 10.1136/heartjnl-2013-304276.
[247] Brignole M., Auricchio A., Baron-Esquivias, G Bordachar P., Boriani G. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association . Europace 2013; 15(8): 1070–118. Doi: 10.1093/europace/eut206.
[248] Brignole M., Vardas P., Hoffman E., Huikuri H., Moya A., Ricci R., Sulke N., Wieling W., Committee ESD., Auricchio A., et al. Indications for the use of diagnostic implantable and external ECG loop recorders. Europace 2009; 11(5): 671–87. Doi: 10.1093/europace/eup097.
[249] Frangini PA., Cecchin F., Jordao L., Martuscello M., Alexander ME., Triedman JK., Walsh EP., Berul CI. How revealing are insertable loop recorders in pediatrics? Pacing Clin Electrophysiol 2008; 31(3): 338–43. Doi: 10.1111/j.1540-8159.2008.00995.x.
[250] Solano A., Menozzi C., Maggi R., Donateo P., Bottoni N., Lolli G., Tomasi C., Croci F., Oddone D., Puggioni E., et al. Incidence, diagnostic yield and safety of the implantable loop-recorder to detect the mechanism of syncope in patients with and without structural heart disease. Eur Heart J 2004; 25(13): 1116–9. Doi: 10.1016/j.ehj.2004.05.013.
[251] Алехин МН., Бартош-Зеленая СЮ., Берестень НФ. Стандартизация проведения трансторакальной эхокардиографии у взрослых: консенсус экспертов Российской ассоциации специалистов ультразвуковой диагностики в медицине (РАСУДМ) и Российской ассоциации специалистов функциональной диагностики (РАСФД). Ультразвуковая и Функциональная Диагностика 2021; 2: 63–79. Doi: 10.24835/1607-0771-2021-2-63-79. – EDN MUCMFC.
[252] Мареев ЮВ., Джиоева ОН., Зоря ОТ., Писарюк АС., Вербило СЛ., Скалецкий К. Фокусное ультразвуковое исследование в практике врача-кардиолога. Российский согласительный документ. Кардиология 2021; 61(11): 4–23. Doi: 10.18087/CARDIO.2021.11.N1812.
[253] Mitchell C., Rahko PS., Blauwet LA., Canaday B., Finstuen JA., Foster MC., Horton K., Ogunyankin KO., Palma RA., Velazquez EJ., et al. Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults: Recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr 2018; 32(1): 1–64. Doi: 10.1016/j.echo.2018.06.004.
[254] Lang RM., Badano LP., Mor-Avi V., Afilalo J., Armstrong A., Ernande L., Flachskampf FA., Foster E., Goldstein SA., Kuznetsova T., et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American society of echocardiography and the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging 2015; 16(3): 233–71. Doi: 10.1093/ehjci/jev014.
[255] Cerqueira M., Weissman N., Dilsizian V., Jacobs A., Kaul S., Laskey W., Pennell D., Rumberger J., Ryan T., MS V. Standardized Myocardial Segmentation and Nomenclature for Tomographic Imaging of the Heart A Statement for Healthcare Professionals From the Cardiac Imaging Committee. Circulation 2002; 105(4): 539–42. Doi: 10.1161/hc0402.102975.
[256] Flachskampf F., Badano L., Daniel W., Feneck R., Fox K., Fraser A., Pasquet A., Pepi M., Perez de Isla L., Zamorano J., et al. Recommendations for Transoesophageal Echocardiography: Update 2010. Eur J Echocardiogr 2010; 11(7): 557–76. Doi: 10.1093/EJECHOCARD/JEQ057.
[257] Nagueh S., Smiseth O., Appleton C., Byrd B 3rd., Dokainish H., Edvardsen T., Flachskampf F. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Hear J Cardiovasc Imaging 2016; 17(12): 1321–60. Doi: 10.1093/ehjci/jew082.
[258] Senior R., Becher H., Monaghan M., Agati L., Zamorano J., Vanoverschelde JL., Nihoyannopoulos P. Contrast echocardiography: evidence-based recommendations by European Association of Echocardiography. Eur J Echocardiogr 2009; 10(2): 194–212.
[259] Klues HG., Schiffers A., Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: Morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol 1995; 26(7): 1699–708. Doi: 10.1016/0735-1097(95)00390-8.
[260] Maron BJ., Casey SA., Hauser RG., Aeppli DM. Clinical course of hypertrophic cardiomyopathy with survival to advanced age. J Am Coll Cardiol 2003; 42(5): 882–8. Doi: 10.1016/S0735-1097(03)00855-6.
[261] Maron BJ., Rowin EJ., Maron MS., Braunwald E. Nonobstructive Hypertrophic Cardiomyopathy Out of the Shadows: Known from the Beginning but Largely Ignored … Until Now. Am J Med 2017; 130(2): 119–23. Doi: 10.1016/j.amjmed.2016.09.015.
[262] Maron MS., Olivotto I., Zenovich AG., Link MS., Pandian NG., Kuvin JT., Nistri S., Cecchi F., Udelson JE., Maron BJ. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 2006; 114(21): 2232–9. Doi: 10.1161/CIRCULATIONAHA.106.644682.
[263] Elliott P., Gimeno J., Tomé M., McKenna W. Left ventricular outflow tract obstruction and sudden death in hypertrophic cardiomyopathy. Eur Heart J 2006; 27(24): 3073–4. Doi: 10.1093/eurheartj/ehl383.
[264] Spirito P., Bellone P., Harris KM., Bernabò P., Bruzzi P., Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000; 342(24): 1778–85. Doi: 10.1056/NEJM200006153422403.
[265] Belenkie I., MacDonald RPR., Smith ER. Localized septal hypertrophy: Part of the spectrum of hypertrophic cardiomyopathy or an incidental echocardiographic finding? Am Heart J 1988; 115(2): 385–90. Doi: 10.1016/0002-8703(88)90486-3.
[266] Gardin J., Palabrica T., Dubria S., Pandian NG., Knoll M., Mclnerney K., Allfie A., Caldeira M., Dabestani A., Henry WL. Localized basal ventricular septal hypertrophy - prevalence, functional and clinical correlates in a population referred for echocardiography. Am J Noninvas Card 1998; 6(1): 5–8.
[267] Losi MA., Nistri S., Galderisi M., Betocchi S., Cecchi F., Olivotto I., Agricola E., Ballo P., Buralli S., D’Andrea A., et al. Echocardiography in patients with hypertrophic cardiomyopathy: Usefulness of old and new techniques in the diagnosis and pathophysiological assessment. Cardiovasc Ultrasound 2010; 8(1): Article number: 7. Doi: 10.1186/1476-7120-8-7.
[268] Alvares RF., Goodwin JF. Non-invasive assessment of diastolic function in hypertrophic cardiomyopathy on and off beta adrenergic blocking drugs. Br Heart J 1982; 48(3): 204–12. Doi: 10.1136/hrt.48.3.204.
[269] Biagini E., Spirito P., Rocchi G., Ferlito M., Rosmini S., Lai F., Lorenzini M., Terzi F., Bacchi-Reggiani L., Boriani G., et al. Prognostic Implications of the Doppler Restrictive Filling Pattern in Hypertrophic Cardiomyopathy. Am J Cardiol 2009; 104(12): 1727–31. Doi: 10.1016/j.amjcard.2009.07.057.
[270] Matsumura Y., Elliott PM., Virdee MS., Sorajja P., Doi Y., McKenna WJ. Left ventricular diastolic function assessed using Doppler tissue imaging in patients with hypertrophic cardiomyopathy: Relation to symptoms and exercise capacity. Heart 2002; 87(3): 247–51. Doi: 10.1136/heart.87.3.247.
[271] Kubo T., Gimeno JR., Bahl A., Steffensen U., Steffensen M., Osman E., Thaman R., Mogensen J., Elliott PM., Doi Y., et al. Prevalence, Clinical Significance, and Genetic Basis of Hypertrophic Cardiomyopathy With Restrictive Phenotype. J Am Coll Cardiol 2007; 49(25): 2419–26. Doi: 10.1016/j.jacc.2007.02.061.
[272] Nagueh SF., Appleton CP., Gillebert TC., Marino PN., Oh JK., Smiseth OA., Waggoner AD., Flachskampf FA., Pellikka PA., Evangelisa A. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2009; 10(2): 165–93. Doi: 10.1093/EJECHOCARD/JEP007.
[273] Dimitrow PP., Bober M., Michałowska J., Sorysz D. Left ventricular outflow tract gradient provoked by upright position or exercise in treated patients with hypertrophic cardiomyopathy without obstruction at rest. Echocardiography 2009; 26(5): 513–20. Doi: 10.1111/j.1540-8175.2008.00851.x.
[274] Nistri S., Olivotto I., Maron MS., Grifoni C., Baldini K., Baldi M., Sgalambro A., Cecchi F., Maron BJ. Timing and significance of exercise-induced left ventricular outflow tract pressure gradients in hypertrophic cardiomyopathy. Am J Cardiol 2010; 106(9): 1301–6. Doi: 10.1016/j.amjcard.2010.06.057.
[275] Olivotto I., Montereggi A., Mazzuoli F., Cecchi F. Clinical utility and safety of exercise testing in patients with hypertrophic cardiomyopathy. G Ital Cardiol 1999; 29: 11–9.
[276] Sadoul N., Prasad K., Elliott PM., Bannerjee S., Frenneaux MP., McKenna WJ. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 1997; 96(9): 2987–91. Doi: 10.1161/01.CIR.96.9.2987.
[277] Tower-Rader A., Betancor J., Lever HM., Desai MY. A Comprehensive Review of Stress Testing in Hypertrophic Cardiomyopathy: Assessment of Functional Capacity, Identification of Prognostic Indicators, and Detection of Coronary Artery Disease. J Am Soc Echocardiogr 2017; 30(9): 829–44. Doi: 10.1016/j.echo.2017.05.017.
[278] Cardim N., Galderisi M., Edvardsen T., Plein S., Popescu BA., D’Andrea A., Bruder O., Cosyns B., Davin L., Donal E., et al. Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: An expert consensus of the European Association of Cardiovascular Imaging Endorsed by the Saudi Heart Association. Eur Heart J Cardiovasc Imaging 2015; 16(3): 280. Doi: 10.1093/ehjci/jeu291.
[279] Kim MS., Klein AJ., Groves BM., Quaife RA., Salcedo EE. Left Ventricular Outflow Tract Obstruction in the Presence of Asymmetric Septal Hypertrophy and Accessory Mitral Valve Tissue Treated With Alcohol Septal Ablation. Eur J Echocardiogr 2008; 9(5): 720–4. Doi: 10.1093/EJECHOCARD/JEN152.
[280] Monakier D., Woo A., Puri T., Schwartz L., Ross J., Jamorski M., Yang H., Liu Z., Vannan M., Wigle ED., et al. Usefulness of myocardial contrast echocardiographic quantification of risk area for predicting postprocedural complications in patients undergoing septal ethanol ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol 2004; 94(12): 1515–22. Doi: 10.1016/j.amjcard.2004.08.030.
[281] Wallace EL., Thompson JJ., Faulkner MW., Gurley JC., Smith MD. Septal perforator anatomy and variability of perfusion bed by myocardial contrast echocardiography: A study of hypertrophic cardiomyopathy patients undergoing alcohol septal ablation. J Interv Cardiol 2013; 26(6): 604–12. Doi: 10.1111/joic.12068.
[282] Spirito P., Autore C., Formisano F., Assenza GE., Biagini E., Haas TS., Bongioanni S., Semsarian C., Devoto E., Musumeci B., et al. Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors. Am J Cardiol 2014; 113(9): 1550–5. Doi: 10.1016/j.amjcard.2014.01.435.
[283] Grigg LE., Wigle ED., Williams WG., Daniel LB., Rakowski H. Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy: Clarification of pathophysiology and importance in intraoperative decision making. J Am Coll Cardiol 1992; 20(1): 42–52. Doi: 10.1016/0735-1097(92)90135-A.
[284] Oki T., Fukuda N., Iuchi A., Tabata T., Tanimoto M., Manabe K., Kageji Y., Sasaki M., Hama M., Ito S. Transesophageal echocardiographic evaluation of mitral regurgitation in hypertrophic cardiomyopathy: Contributions of eccentric left ventricular hypertrophy and related abnormalities of the mitral complex. J Am Soc Echocardiogr 1995; 8(4): 503–10. Doi: 10.1016/S0894-7317(05)80338-4.
[285] Yu EHC., Omran AS., Wigle ED., Williams WG., Siu SC., Rakowski H. Mitral regurgitation in hypertrophic obstructive cardiomyopathy: Relationship to obstruction and relief with myectomy. J Am Coll Cardiol 2000; 36(7): 2219–25. Doi: 10.1016/S0735-1097(00)01019-6.
[286] Marwick TH., Stewart WJ., Lever HM., Lytle BW., Rosenkranz ER., Duffy CI., Salcedo EE. Benefits of intraoperative echocardiography in the surgical management of hypertrophic cardiomyopathy. J Am Coll Cardiol 1992; 20(5): 1066–72. Doi: 10.1016/0735-1097(92)90359-U.
[287] Huurman R., Van Der Velde N., Schinkel AFL., Hassing HC., Budde RPJ., Van Slegtenhorst MA., Verhagen JMA., Hirsch A., Michels M. Contemporary family screening in hypertrophic cardiomyopathy: the role of cardiovascular magnetic resonance. Eur Hear Journal Cardiovasc Imaging 2022; 23(9): 1144–54. Doi: 10.1093/EHJCI/JEAC099.
[288] Bois JP., Geske JB., Foley TA., Ommen SR., Pellikka PA. Comparison of Maximal Wall Thickness in Hypertrophic Cardiomyopathy Differs Between Magnetic Resonance Imaging and Transthoracic Echocardiography. Am J Cardiol 2017; 119(4): 643–50. Doi: 10.1016/J.AMJCARD.2016.11.010.
[289] Гурщенков АВ., Моисеева ОМ., Зайцев ВВ., Хазов ПА., Ишмухаметов ГИ., Гордеев МЛ. Анализ анатомии межжелудочковой перегородки при обструктивных формах гипертрофической кардиомиопатии. Кардиология и Сердечно-Сосудистая Хирургия 2025; 18(1): 15–22. Doi: 10.17116/kardio20251801115.
[290] Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 2005; 112(13): 2047–60. Doi: 10.1161/CIRCULATIONAHA.104.489187.
[291] Gillmore JD., Maurer MS., Falk RH., Merlini G., Damy T., Dispenzieri A., Wechalekar AD., Berk JL., Quarta CC., Grogan M., et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016; 133(24): 2404–12. Doi: 10.1161/CIRCULATIONAHA.116.021612.
[292] Quarta CC., Guidalotti PL., Longhi S., Pettinato C., Leone O., Ferlini A., Biagini E., Grigioni F., Bacchi-Reggiani ML., Lorenzini M., et al. Defining the diagnosis in echocardiographically suspected senile systemic amyloidosis. JACC Cardiovasc Imaging 2012; 5(7): 755–8. Doi: 10.1016/j.jcmg.2012.02.015.
[293] Syed IS., Glockner JF., Feng DL., Araoz PA., Martinez MW., Edwards WD., Gertz MA., Dispenzieri A., Oh JK., Bellavia D., et al. Role of Cardiac Magnetic Resonance Imaging in the Detection of Cardiac Amyloidosis. JACC Cardiovasc Imaging 2010; 3(2): 155–64. Doi: 10.1016/j.jcmg.2009.09.023.
[294] Vogelsberg H., Mahrholdt H., Deluigi CC., Yilmaz A., Kispert EM., Greulich S., Klingel K., Kandolf R., Sechtem U. Cardiovascular Magnetic Resonance in Clinically Suspected Cardiac Amyloidosis. Noninvasive Imaging Compared to Endomyocardial Biopsy. J Am Coll Cardiol 2008; 51(10): 1022–30. Doi: 10.1016/j.jacc.2007.10.049.
[295] Dungu JN., Valencia O., Pinney JH., Gibbs SDJ., Rowczenio D., Gilbertson JA., Lachmann HJ., Wechalekar A., Gillmore JD., Whelan CJ., et al. CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC Cardiovasc Imaging 2014; 7(2): 133–42. Doi: 10.1016/J.JCMG.2013.08.015.
[296] Moon JCC., Fisher NG., McKenna WJ., Pennell DJ. Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart 2004; 90(6): 645–9. Doi: 10.1136/hrt.2003.014969.
[297] O’Hanlon R., Assomull RG., Prasad SK. Use of cardiovascular magnetic resonance for diagnosis and management in hypertrophic cardiomyopathy. Curr Cardiol Rep 2007; 9(1): 51–6. Doi: 10.1007/s11886-007-0010-0.
[298] Webb J., Fovargue L., Tøndel K., Porter B., Sieniewicz B., Gould J., Rinaldi CA., Ismail T., Chiribiri A., Carr-White G. The Emerging Role of Cardiac Magnetic Resonance Imaging in the Evaluation of Patients with HFpEF. Curr Heart Fail Rep 2018; 15(1): 1–9. Doi: 10.1007/s11897-018-0372-1.
[299] Patel P., Dhillon A., Popovic ZB., Smedira NG., Rizzo J., Thamilarasan M., Agler D., Lytle BW., Lever HM., Desai MY. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy patients without severe septal hypertrophy: Implications of mitral valve and papillary muscle abnormalities assessed using cardiac magnetic resonance and echocardiography. Circ Cardiovasc Imaging 2015; 8(7): e003132. Doi: 10.1161/CIRCIMAGING.115.003132.
[300] Olivotto I., Maron MS., Autore C., Lesser JR., Rega L., Casolo G., De Santis M., Quarta G., Nistri S., Cecchi F., et al. Assessment and Significance of Left Ventricular Mass by Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy. J Am Coll Cardiol 2008; 52(7): 559–66. Doi: 10.1016/j.jacc.2008.04.047.
[301] Rudolph A., Abdel-Aty H., Bohl S., Boyé P., Zagrosek A., Dietz R., Schulz-Menger J. Noninvasive Detection of Fibrosis Applying Contrast-Enhanced Cardiac Magnetic Resonance in Different Forms of Left Ventricular Hypertrophy. Relation to Remodeling. J Am Coll Cardiol 2009; 53(3): 284–91. Doi: 10.1016/j.jacc.2008.08.064.
[302] Gruner C., Chan RH., Crean A., Rakowski H., Rowin EJ., Care M., Deva D., Williams L., Appelbaum E., Gibson CM., et al. Significance of left ventricular apical-basal muscle bundle identified by cardiovascular magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Eur Heart J 2014; 35(39): 2706–13. Doi: 10.1093/eurheartj/ehu154.
[303] Brouwer WP., Germans T., Head MC., Velden J van der., Heymans MW., Christiaans I., Houweling AC., Wilde AA., Rossum AC van. Multiple myocardial crypts on modified long-axis view are a specific finding in pre-hypertrophic HCM mutation carriers. Eur Hear J Cardiovasc Imaging 2012; 13(4): 292–7. Doi: 10.1093/ehjci/jes005.
[304] Sado DM., White SK., Piechnik SK., Banypersad SM., Treibel T., Captur G., Fontana M., Maestrini V., Flett AS., Robson MD., et al. Identification and assessment of anderson-fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging 2013; 6(3): 392–8. Doi: 10.1161/CIRCIMAGING.112.000070.
[305] Maron BJ., Pelliccia A., Spirito P. Cardiac disease in young trained athletes: Insights into methods for distinguishing athlete’s heart from structural heart disease, with particular emphasis on hypertrophic cardiomyopathy. Circulation 1995; 91(5): 1596–601. Doi: 10.1161/01.CIR.91.5.1596.
[306] Schroeder S., Achenbach S., Bengel F., Burgstahler C., Cademartiri F., Feyter P de., George R., Kaufmann P., Kopp AF., Knuuti J., et al. Cardiac Computed Tomography: Indications, Applications, Limitations, and Training Requirements: Report of a Writing Group Deployed by the Working Group Nuclear Cardiology and Cardiac CT of the European Society of Cardiology and the European Council of Nuc. Eur Hear J 2008; 29(4): 531–56.
[307] Esposito A., Colantoni C., De Cobelli F., Del Vecchio A., Palmisano A., Calandrino R., Del Maschio A. Multidetector computed tomography for coronary stents imaging: High-voltage (140-KVP) prospective ecg-triggered versus standard-voltage (120-kvp) retrospective ecg-gated helical scanning. J Comput Assist Tomogr 2013; 37(3): 395–401. Doi: 10.1097/RCT.0b013e3182873559.
[308] Shiozaki AA., Senra T., Arteaga E., Martinelli Filho M., Pita CG., Ávila LFR., Parga Filho JR., Mady C., Kalil-Filho R., Bluemke DA., et al. Myocardial fibrosis detected by cardiac CT predicts ventricular fibrillation/ventricular tachycardia events in patients with hypertrophic cardiomyopathy. J Cardiovasc Comput Tomogr 2013; 7(3): 173–81. Doi: 10.1016/j.jcct.2013.04.002.
[309] Rapezzi C., Quarta CC., Guidalotti PL., Longhi S., Pettinato C., Leone O., Ferlini A., Salvi F., Gallo P., Gagliardi C., et al. Usefulness and limitations of 99mTc-3, 3-diphosphono-1, 2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging 2011; 38(3): 470–8. Doi: 10.1007/s00259-010-1642-7.
[310] Rapezzi C., Quarta CC., Guidalotti PL., Pettinato C., Fanti S., Leone O., Ferlini A., Longhi S., Lorenzini M., Reggiani LB., et al. Role of 99mTc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging 2011; 4(6): 659–70. Doi: 10.1016/j.jcmg.2011.03.016.
[311] Dorbala S., Ando Y., Bokhari S., Dispenzieri A., Falk RH., Ferrari VA., Fontana M., Gheysens O., Gillmore JD., Glaudemans AWJM., et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging. J Card Fail 2019; 25(11): e1–39. Doi: 10.1016/j.cardfail.2019.08.001.
[312] Dorbala S., Ando Y., Bokhari S., Dispenzieri A., Falk RH., Ferrari VA., Fontana M., Gheysens O., Gillmore JD., Glaudemans AWJM., et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2—Diagnostic Criteria and Appropriate Utilization. J Card Fail 2019; 25(11): 854–65. Doi: 10.1016/j.cardfail.2019.08.002.
[313] Kawai C., Sakurai T., Fujiwara H., Matsumori A., Yui Y. Hypertrophic obstructive and non-obstructive cardiomyopathy in Japan. Diagnosis of the disease with special reference to endomyocardial catheter biopsy. Eur Hear J 1983; 4(1): 121–5.
[314] Scalone G., Niccoli G., Crea F. Editor’s Choice- Pathophysiology, diagnosis and management of MINOCA: an update. Eur Hear Journal Acute Cardiovasc Care 2019; 8(1): 54–62. Doi: 10.1177/2048872618782414.
[315] Mitsutake R., Miura S ichiro., Sako H., Nishikawa H., Saku K. Usefulness of multi-detector row computed tomography for the management of percutaneous transluminal septal myocardial ablation in patient with hypertrophic obstructive cardiomyopathy. Int J Cardiol 2008; 129(2): 61–3. Doi: 10.1016/j.ijcard.2007.06.132.
[316] Okayama S., Uemura S., Soeda T., Horii M., Saito Y. Role of cardiac computed tomography in planning and evaluating percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy. J Cardiovasc Comput Tomogr 2010; 4(1): 62–5. Doi: 10.1016/j.jcct.2009.10.004.
[317] Villa ADM., Sammut E., Zarinabad N., Carr-White G., Lee J., Bettencourt N., Razavi R., Nagel E., Chiribiri A. Microvascular ischemia in hypertrophic cardiomyopathy: New insights from high-resolution combined quantification of perfusion and late gadolinium enhancement. J Cardiovasc Magn Reson 2016; 18: Article number 4 (2015). Doi: 10.1186/s12968-016-0223-8.
[318] Chen JM., Levin HR., Michler RE., Prusmack CJ., Rose EA., Aaronson KD. Reevaluating the significance of pulmonary hypertension before cardiac transplantation: Determination of optimal thresholds and quantification of the effect of reversibility on perioperative mortality. J Thorac Cardiovasc Surg 1997; 114(4): 627–34. Doi: 10.1016/S0022-5223(97)70053-9.
[319] Kato TS., Takayama H., Yoshizawa S., Marboe C., Schulze PC., Farr M., Naka Y., Mancini D., Maurer MS. Cardiac transplantation in patients with hypertrophic cardiomyopathy. Am J Cardiol 2012; 110(4): 568–74. Doi: 10.1016/j.amjcard.2012.04.030.
[320] Lindelöw B., Andersson B., Waagstein F., Bergh CH. High and low pulmonary vascular resistance in heart transplant candidates. A 5-year follow-up after heart transplantation shows continuous reduction in resistance and no difference in complication rate. Eur Heart J 1999; 20(2): 148–56. Doi: 10.1053/euhj.1998.1155.
[321] Maron MS., Kalsmith BM., Udelson JE., Li W., DeNofrio D. Survival after cardiac transplantation in patients with hypertrophic cardiomyopathy. Circ Hear Fail 2010; 3(5): 574–9. Doi: 10.1161/CIRCHEARTFAILURE.109.922872.
[322] Mehra MR., Kobashigawa J., Starling R., Russell S., Uber PA., Parameshwar J., Mohacsi P., Augustine S., Aaronson K., Barr M. Listing Criteria for Heart Transplantation: International Society for Heart and Lung Transplantation Guidelines for the Care of Cardiac Transplant Candidates-2006. J Hear Lung Transplant 2006; 25(9): 1024–42. Doi: 10.1016/j.healun.2006.06.008.
[323] Torres MF., Perez-Villa F. Heart transplantation in patients with hypertrophic cardiomyopathy. Glob Cardiol Sci Pract 2018; 2018(3): 32. Doi: 10.21542/gcsp.2018.32.
[324] Blomström-Lundqvist C., Scheinman MM., Aliot EM., Alpert JS., Calkins H., Camm AJ., Campbell WB., Haines DE., Kuck KH., Lerman BB., et al. ACC/AHA/ESC Guidelines for the Management of Patients with Supraventricular Arrhythmias - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology. J Am Coll Cardiol 2003; 42(8): 1493–531. Doi: 10.1016/j.jacc.2003.08.013.
[325] Бокерия ЛА., Берсенёва МИ., Маленков ДА. Аритмогенные осложнения гипертрофической кардиомиопатии. Анналы Аритмологии 2010; 7(3): 62–9.
[326] Muresan L., Cismaru G., Martins RP., Bataglia A., Rosu R., Puiu M., Gusetu G., Mada RO., Muresan C., Ispas DR., et al. Recommendations for the use of electrophysiological study: Update 2018. Hell J Cardiol 2019; 60(2): 82–100. Doi: 10.1016/j.hjc.2018.09.002.
[327] Wang W., Lian Z., Rowin EJ., Maron BJ., Maron MS., Link MS. Prognostic Implications of Nonsustained Ventricular Tachycardia in High-Risk Patients With Hypertrophic Cardiomyopathy. Circ Arrhythm Electrophysiol 2017; 10(3): e004604. Doi: 10.1161/CIRCEP.116.004604.
[328] Inada K., Seiler J., Roberts-Thomson KC., Steven D., Rosman J., John RM., Sobieszczyk P., Stevenson WG., Tedrow UB. Substrate characterization and catheter ablation for monomorphic ventricular tachycardia in patients with apical hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 2011; 22(1): 41–8. Doi: 10.1111/j.1540-8167.2010.01875.x.
[329] Lim KK., Maron BJ., Knight BP. Successful catheter ablation of hemodynamically unstable monomorphic ventricular tachycardia in a patient with hypertrophic cardiomyopathy and apical aneurysm. J Cardiovasc Electrophysiol 2009; 20(4): 445–7. Doi: 10.1111/j.1540-8167.2008.01366.x.
[330] Refaat MM., Hotait M., Tseng ZH. Utility of the exercise electrocardiogram testing in sudden cardiac death risk stratification. Ann Noninvasive Electrocardiol 2014; 19(4): 311–8. Doi: 10.1111/anec.12191.
[331] Yi G., Poloniecki J., Dickie S., Elliot PM., Malik M., McKenna WJ. Can the Assessment of Dynamic QT Dispersion on Exercise Electrocardiogram Predict Sudden Cardiac Death in Hypertrophic Cardiomyopathy? Pacing Clin Electrophysiol 2000; 23(11Pt2): 1953–6. Doi: 10.1111/j.1540-8159.2000.tb07060.x.
[332] Nistri S., Olivotto I., Maron MS., Ferrantini C., Coppini R., Grifoni C., Baldini K., Sgalambro A., Cecchi F., Maron BJ. β blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. Am J Cardiol 2012; 110(5): 715–9. Doi: 10.1016/j.amjcard.2012.04.051.
[333] Rowin EJ., Maron BJ., Olivotto I., Maron MS. Role of Exercise Testing in Hypertrophic Cardiomyopathy. JACC Cardiovasc Imaging 2017; 10(11): 1374–86. Doi: 10.1016/j.jcmg.2017.07.016.
[334] Yalçin F., Muderrisoglu H., Korkmaz ME., Ozin B., Baltali M., Yigit F. The effect of dobutamine stress on left ventricular outflow tract gradients in hypertensive patients with basal septal hypertrophy. Angiology 2004; 55(3): 295–301. Doi: 10.1177/000331970405500309.
[335] Mancini DM., Eisen H., Kussmaul W., Mull R., Edmonds LH., Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991; 83(3): 778–86. Doi: 10.1161/01.CIR.83.3.778.
[336] Sharma S., Elliott P., Whyte G., Jones S., Mahon N., Whipp B., McKenna WJ. Utility of cardiopulmonary exercise in the assessment of clinical determinants of functional capacity in hypertrophic cardiomyopathy. Am J Cardiol 2000; 86(2): 162–8. Doi: 10.1016/S0002-9149(00)00854-7.
[337] Колоскова НН., Шаталов КВ., Бокерия ЛА. Определение пикового потребления кислорода: клиническое использование и перспективы. Креативная Кардиология 2014; 2: 20–8.
[338] Coats CJ., Rantell K., Bartnik A., Patel A., Mist B., McKenna WJ., Elliott PM. Cardiopulmonary Exercise Testing and Prognosis in Hypertrophic Cardiomyopathy. Circ Hear Fail 2015; 8(6): 1022–31. Doi: 10.1161/CIRCHEARTFAILURE.114.002248.
[339] Arena R., Owens DS., Arevalo J., Smith K., Mohiddin SA., Mcareavey D., Ulisney KL., Tripodi D., Fananapazir L., Plehn JF. Ventilatory efficiency and resting hemodynamics in hypertrophic cardiomyopathy. Med Sci Sports Exerc 2008; 40(5): 799–805. Doi: 10.1249/MSS.0b013e31816459a1.
[340] Olivotto I., Maron BJ., Montereggi A., Mazzuoli F., Dolara A., Cecchi F. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999; 33(7): 2044–51. Doi: 10.1016/S0735-1097(99)00094-7.
[341] Bennett MK., Gilotra NA., Harrington C., Rao S., Dunn JM., Freitag TB., Halushka MK., Russell SD. Evaluation of the role of endomyocardial biopsy in 851 patients with unexplained heart failure from 2000-2009. Circ Hear Fail 2013; 6(4): 676–84. Doi: 10.1161/CIRCHEARTFAILURE.112.000087.
[342] Leone O., Veinot JP., Angelini A., Baandrup UT., Basso C., Berry G., Bruneval P., Burke M., Butany J., Calabrese F., et al. 2011 Consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol 2012; 21(4): 245–74. Doi: 10.1016/j.carpath.2011.10.001.
[343] Quarta CC., Gonzalez-Lopez E., Gilbertson JA., Botcher N., Rowczenio D., Petrie A., Rezk T., Youngstein T., Mahmood S., Sachchithanantham S., et al. Diagnostic Sensitivity of Abdominal Fat Aspiration in Cardiac Amyloidosis. Eur Hear J 2017; 38(24): 1905–8.
[344] Schönland SO., Hegenbart U., Bochtler T., Mangatter A., Hansberg M., Ho AD., Lohse P., Röcken C. Immunohistochemistry in the classification of systemic forms of amyloidosis: A systematic investigation of 117 patients. Blood 2012; 119(2): 488–93. Doi: 10.1182/blood-2011-06-358507.
[345] Крылова НС., Хашиева ФМ., Демкина АЕ., Ковалевская ЕА., Потешкина НГ. Гипертрофическая кардиомиопатия и артериальная гипертензия: возможно ли сочетание? Сердце Журнал Для Практикующих Врачей 2015; 14(3(83)): 164–9.
[346] Полякова АА., Гудкова АЯ., Крутиков АН., Семернин ЕН., Козленок АВ., Пыко СА., Костарева АА., Шляхто ЕВ. Гипертрофическая кардиомиопатия в старшей возрастной группе: влияние факторов кардиометаболического риска и полиморфизма гена MADD. Артериальная Гипертензия 2018; 24(1): 29–40.
[347] Abel ED., Litwin SE., Sweeney G. Cardiac remodeling in obesity. Physiol Rev 2008: 389–419. Doi: 10.1152/physrev.00017.2007.
[348] Ommen SR., Lopez-Jimenez F. Obesity and hypertrophic cardiomyopathy: Chickens, eggs, and causality: Clinical skills remain the key to caring for patients. J Am Coll Cardiol 2013; 62(5): 458–9. Doi: 10.1016/j.jacc.2013.03.063.
[349] Olivotto I., Maron BJ., Tomberli B., Appelbaum E., Salton C., Haas TS., Gibson CM., Nistri S., Servettini E., Chan RH., et al. Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy. J Am Coll Cardiol 2013; 62(5): 449–57. Doi: 10.1016/j.jacc.2013.03.062.
[350] Di Tommaso L., Stassano P., Mannacio V., Russolillo V., Monaco M., Pinna G., Vosa C. Asymmetric septal hypertrophy in patients with severe aortic stenosis: The usefulness of associated septal myectomy. J Thorac Cardiovasc Surg 2013; 145(1): 171–5. Doi: 10.1016/j.jtcvs.2011.10.096.
[351] Dweck MR., Joshi S., Murigu T., Gulati A., Alpendurada F., Jabbour A., MacEira A., Roussin I., Northridge DB., Kilner PJ., et al. Left ventricular remodeling and hypertrophy in patients with aortic stenosis: Insights from cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2012; 14(1): 50. Doi: 10.1186/1532-429X-14-50.
[352] Katayama M., Panse PM., Kendall CB., Daniels JR., Cha SS., Fortuin FD., Sweeney JP., DeValeria PA., Lanza LA., Belohlavek M., et al. Left ventricular septal hypertrophy in elderly patients with aortic stenosis. J Ultrasound Med 2017; 37(1): 217–24. Doi: 10.1002/jum.14320.
[353] Maron BJ., Edwards JE., Epstein SE. Disproportionate ventricular septal thickening in patients with systemic hypertension. Chest 1978; 73(4): 466–70. Doi: 10.1378/chest.73.4.466.
[354] Rodrigues JCL., Amadu AM., Dastidar AG., Hassan N., Lyen SM., Lawton CB., Ratcliffe LE., Burchell AE., Hart EC., Hamilton MCK., et al. Prevalence and Predictors of Asymmetric Hypertensive Heart Disease: Insights From Cardiac and Aortic Function With Cardiovascular Magnetic Resonance. Eur Hear J Cardiovasc Imaging 2016; 17(12): 1405–13.
[355] Tuseth N., Cramariuc D., Rieck ÅE., Wachtell K., Gerdts E. Asymmetric septal hypertrophy - A marker of hypertension in aortic stenosis (a SEAS substudy). Blood Press 2010; 19(3): 140–4. Doi: 10.3109/08037051.2010.481816.
[356] Van Straten AHM., Soliman Hamad MA., Peels KCH., Van Den Broek KC., Ter Woorst JFJ., Elenbaas TW., Van Dantzig JM. Increased septum wall thickness in patients undergoing aortic valve replacement predicts worse late survival. Ann Thorac Surg 2012; 94(1): 66–71. Doi: 10.1016/j.athoracsur.2012.03.027.
[357] Shapiro LM., Howat AP., Crean PA., Westgate CJ. An echocardiographic study of localized subaortic hypertrophy. Eur Heart J 1986; 7(2): 127–32. Doi: 10.1093/oxfordjournals.eurheartj.a062034.
[358] Gutiérrez-Barrios A., Camacho-Jurado F., Díaz-Retamino E., Gamaza-Chulián S., Agarrado-Luna A., Oneto-Otero J., Del Rio-Lechuga A., Benezet-Mazuecos J. Invasive assessment of coronary microvascular dysfunction in hypertrophic cardiomyopathy: The index of microvascular resistance. Cardiovasc Revascularization Med 2015; 16(7): 426–8. Doi: 10.1016/j.carrev.2015.06.008.
[359] Ismail TF., Hsu LY., Greve AM., Gonçalves C., Jabbour A., Gulati A., Hewins B., Mistry N., Wage R., Roughton M., et al. Coronary microvascular ischemia in hypertrophic cardiomyopathy - A pixel-wise quantitative cardiovascular magnetic resonance perfusion study. J Cardiovasc Magn Reson 2014; 16(1): 49. Doi: 10.1186/s12968-014-0049-1.
[360] Olivotto I., Girolami F., Sciagr R., Ackerman MJ., Sotgia B., Bos JM., Nistri S., Sgalambro A., Grifoni C., Torricelli F., et al. Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations. J Am Coll Cardiol 2011; 58(8): 839–48. Doi: 10.1016/j.jacc.2011.05.018.
[361] Raissuni Z., Doghmi N., Mousseaux E., Cherti M., Redheuil A. Hypertrophic cardiomyopathy mimicking STEMI: The role of cardiac magnetic resonance imaging in the detection of microvascular coronary dysfunction. Diagn Interv Imaging 2014; 95(11): 1111–2. Doi: 10.1016/j.diii.2013.12.020.
[362] Timmer SAJ., Knaapen P. Coronary Microvascular Function, Myocardial Metabolism, and Energetics in Hypertrophic Cardiomyopathy: Insights From Positron Emission Tomography. Eur Hear J Cardiovasc Imaging 2013; 14(2): 95–101.
[363] Zhang YD., Li M., Qi L., Wu CJ., Wang X. Hypertrophic cardiomyopathy: Cardiac structural and microvascular abnormalities as evaluated with multi-parametric MRI. Eur J Radiol 2015; 84(8): 1480–6. Doi: 10.1016/j.ejrad.2015.04.028.
[364] Zipes DP., Camm AJ., Borggrefe M., Buxton AE., Chaitman B., Fromer M., Gregoratos G., Klein G., Moss AJ., Myerburg RJ., et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Circulation 2006; 114(10): e385-484. Doi: 10.1161/CIRCULATIONAHA.106.178233.
[365] Basavarajaiah S., Wilson M., Whyte G., Shah A., McKenna W., Sharma S. Prevalence of Hypertrophic Cardiomyopathy in Highly Trained Athletes. Relevance to Pre-Participation Screening. J Am Coll Cardiol 2008; 51(10): 1033–9. Doi: 10.1016/j.jacc.2007.10.055.
[366] Malhotra A., Sharma S. Hypertrophic cardiomyopathy in athletes. Eur Cardiol Rev 2017; 12(2): 80–2. Doi: 10.15420/ecr.2017:12:1.
[367] Pelliccia A., Corrado D., Bjã¸rnstad HH., Panhuyzen-Goedkoop N., Urhausen A., Carre F., Anastasakis A., Vanhees L., Arbustini E., Priori S. Recommendations for participation in competitive sport and leisure-time physical activity in individuals with cardiomyopathies, myocarditis and pericarditis. Eur J Prev Cardiol 2006; 13(6): 876–85. Doi: 10.1097/01.hjr.0000238393.96975.32.
[368] Liebregts M., Faber L., Jensen MK., Vriesendorp PA., Hansen PR., Seggewiss H., Horstkotte D., Adlova R., Michels M., Bundgaard H., et al. Validation of the HCM Risk-SCD model in patients with hypertrophic cardiomyopathy following alcohol septal ablation. Europace 2018; 20(FI2): 198–203. Doi: 10.1093/europace/eux251.
[369] Vriesendorp PA., Schinkel AFL., Liebregts M., Theuns DAMJ., Van Cleemput J., Ten Cate FJ., Willems R., Michels M. Validation of the 2014 European Society of Cardiology Guidelines Risk Prediction Model for the Primary Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy. Circ Arrhythmia Electrophysiol 2015; 8(4): 829–35. Doi: 10.1161/CIRCEP.114.002553.
[370] Tsuda T., Hayashi K., Konno T., Sakata K., Fujita T., Hodatsu A., Nagata Y., Teramoto R., Nomura A., Tanaka Y., et al. J Waves for Predicting Cardiac Events in Hypertrophic Cardiomyopathy. JACC Clin Electrophysiol 2017; 3(10): 1136–42. Doi: 10.1016/J.JACEP.2017.03.010.
[371] Veselka J., Liebregts M., Cooper R., Faber L., Januska J., Kashtanov M., Tesarkova KH., Hansen PR., Seggewiss H., Shloydo E., et al. Prediction of Sudden Cardiac Arrest After Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: ASA-SCARRE Risk Score. Am J Cardiol 2022; 184: 120–6. Doi: 10.1016/J.AMJCARD.2022.08.028.
[372] Spoladore R., Maron MS., D’Amato R., Camici PG., Olivotto I. Pharmacological Treatment Options for Hypertrophic Cardiomyopathy: High Time for Evidence. Eur Hear J 2012; 33(14): 1724–33.
[373] Patten M., Pecha S., Aydin A. Atrial Fibrillation in Hypertrophic Cardiomyopathy: Diagnosis and Considerations for Management. J Atr Fibrillation 2018; 10(5): 1556.
[374] Rujirachun P., Charoenngam N., Wattanachayakul P., Winijkul A., Owattanapanich W., Ungprasert P. Efficacy and safety of direct oral anticoagulants (DOACs) versus vitamin K antagonist (VKA) among patients with atrial fibrillation and hypertrophic cardiomyopathy: a systematic review and meta-analysis. Acta Cardiol 2019; 75(8): 724–31. Doi: 10.1080/00015385.2019.1668113.
[375] Maron BJ., Casey SA., Olivotto I., Sherrid M V., Semsarian C., Autore C., Ahmed A., Boriani G., Francia P., Winters SL., et al. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators. Circ Arrhythm Electrophysiol 2018; 11(4). Doi: 10.1161/CIRCEP.117.005820.
[376] Klopotowski M., Kukula K., Jamiolkowski J., Oreziak A., Dabrowski M., Chmielak Z., Witkowski A. Sudden Cardiac Death Risk over Time in HCM Patients with Implantable Cardioverter-Defibrillator. J Clin Med 2022; 11(6). Doi: 10.3390/JCM11061633.
[377] Lambiase PD., Barr C., Theuns DAMJ., Knops R., Neuzil P., Johansen JB., Hood M., Pedersen S., Kääb S., Murgatroyd F., et al. Worldwide Experience With a Totally Subcutaneous Implantable Defibrillator: Early Results From the EFFORTLESS S-ICD Registry. Eur Hear J 2014; 35(25): 1657–65.
[378] Dearani JA., Ommen SR., Gersh BJ., Schaff H V., Danielson GK. Surgery Insight: Septal myectomy for obstructive hypertrophic cardiomyopathy - The Mayo Clinic experience. Nat Clin Pract Cardiovasc Med 2007; 4(9): 503–12. Doi: 10.1038/ncpcardio0965.
[379] Leonardi RA., Kransdorf EP., Simel DL., Wang A. Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy comparative rates of overall mortality and sudden cardiac death after treatment. Circ Cardiovasc Interv 2010; 3(2): 97–104. Doi: 10.1161/CIRCINTERVENTIONS.109.916676.
[380] Afanasyev A V., Bogachev-Prokophiev A V., Ovcharov MA., Pivkin AN., Zalesov AS., Budagaev SA., Sharifulin RM., Zheleznev SI., Karaskov AM. Single-Centre Experience of Surgical Myectomy for Hypertrophic Obstructive Cardiomyopathy. Hear Lung Circ 2019; 29(6): 949–55. Doi: 10.1016/j.hlc.2019.07.009.
[381] Visseren FLJ., Mach F., Smulders YM., Carballo D., Koskinas KC., Bäck M., Benetos A., Biffi A., Boavida J-M., Capodanno D., et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). Rev Esp Cardiol (Engl Ed) 2022; 75(5): 429. Doi: 10.1016/J.REC.2022.04.003.
[382] Ammirati E., Contri R., Coppini R., Cecchi F., Frigerio M., Olivotto I. Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. Eur J Heart Fail 2016; 18(9): 1106–18. Doi: 10.1002/ejhf.541.
[383] Udelson JE., Bonow RO., O’Gara PT., Maron BJ., Van Lingen A., Bacharach SL., Epstein SE. Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 1989; 79(5): 1052–60. Doi: 10.1161/01.CIR.79.5.1052.
[384] Sherrid M V., Shetty A., Winson G., Kim B., Musat D., Alviar CL., Homel P., Balaram SK., Swistel DG. Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with β-blockade or verapamil. Circ Hear Fail 2013; 6(4): 694–702. Doi: 10.1161/CIRCHEARTFAILURE.112.000122.
[385] V. Sherrid M. Drug Therapy for Hypertrophic Cardiomypathy: Physiology and Practice. Curr Cardiol Rev 2016; 12(1): 52–65. Doi: 10.2174/1573403x1201160126125403.
[386] Monda E., Lioncino M., Palmiero G., Franco F., Rubino M., Cirillo A., Verrillo F., Fusco A., Caiazza M., Mazzella M., et al. Bisoprolol for treatment of symptomatic patients with obstructive hypertrophic cardiomyopathy. The BASIC (bisoprolol AS therapy in hypertrophic cardiomyopathy) study. Int J Cardiol 2022; 354: 22–8. Doi: 10.1016/J.IJCARD.2022.03.013.
[387] Dybro AM., Rasmussen TB., Nielsen RR., Pedersen ALD., Andersen MJ., Jensen MK., Poulsen SH. Metoprolol Improves Left Ventricular Longitudinal Strain at Rest and during Exercise in Obstructive Hypertrophic Cardiomyopathy. J Am Soc Echocardiogr 2023; 36(2): 196–204. Doi: 10.1016/J.ECHO.2022.09.008.
[388] Toshima H., Koga Y., Nagata H., Toyomasu K., Itaya KI., Matoba T. Comparable effects of oral diltiazem and verapamil in the treatment of hypertrophic cardiomyopathy. Double-blind crossover study. Jpn Hear J 1986; 27(5): 701–15. Doi: 10.1536/ihj.27.701.
[389] Bonow RO., Dilsizian V., Rosing DR., Maron BJ., Bacharach SL., Green M V. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: Short- and long-term effects. Circulation 1985; 72(4): 853–64. Doi: 10.1161/01.CIR.72.4.853.
[390] Tezuka A., Higo K., Nakamukae Y., Nishihara S., Kamikawa M., Shimofuku C., Kawazoe K., Ohishi M. Bisoprolol successfully improved the intraventricular pressure gradient in a patient with midventricular obstructive hypertrophic cardiomyopathy with an apex aneurysm due to apical myocardial damage. Intern Med 2019; 58(4): 535–9. Doi: 10.2169/internalmedicine.0997-18.
[391] Said SM., Schaff H V., Abel MD., Dearani JA. Transapical approach for apical myectomy and relief of midventricular obstruction in hypertrophic cardiomyopathy. J Card Surg 2012; 27(4): 443–8. Doi: 10.1111/j.1540-8191.2012.01475.x.
[392] Богачев-Прокофьев АВ., Железнев СИ., Фоменко МС., Шарифулин РМ., Афанасьев АВ., Малахова ОЮ., Караськов АМ. Эффективность расширенной миоэктомии у пациентов с желудочковой обструкцией при гипертрофической кардиомиопатии. Кардиология 2017; 57(5): 38–43.
[393] Nguyen A., Schaff H V. Surgical Myectomy: Subaortic, Midventricular, and Apical. Cardiol Clin 2019; 37(1): 95–104. Doi: 10.1016/J.CCL.2018.08.006.
[394] Schaff H V., Brown ML., Dearani JA., Abel MD., Ommen SR., Sorajja P., Tajik AJ., Nishimura RA. Apical myectomy: a new surgical technique for management of severely symptomatic patients with apical hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg 2010; 139(3): 634–40. Doi: 10.1016/J.JTCVS.2009.07.079.
[395] Batzner A., Schäfers H-J., Borisov K V., Seggewiß H. Hypertrophic Obstructive Cardiomyopathy. Dtsch Arztebl Int 2019; 116(4): 47–53. Doi: 10.3238/ARZTEBL.2019.0047.
[396] Epstein SE., Rosing DR. Verapamil: Its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation 1981; 64(3): 437–41. Doi: 10.1161/01.CIR.64.3.437.
[397] Maron BJ., Rowin EJ., Casey SA., Link MS., Lesser JR., Chan RHM., Garberich RF., Udelson JE., Maron MS. Hypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management Strategies. J Am Coll Cardiol 2015; 65(18): 1915–28. Doi: 10.1016/J.JACC.2015.02.061.
[398] Charron P., Elliott PM., Gimeno JR., Caforio ALP., Kaski JP., Tavazzi L., Tendera M., Maupain C., Laroche C., Rubis P., et al. The Cardiomyopathy Registry of the EURObservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies. Eur Heart J 2018; 39(20): 1784–93. Doi: 10.1093/EURHEARTJ/EHX819.
[399] Olivotto I., Cecchi F., Casey SA., Dolara A., Traverse JH., Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001; 104(21): 2517–24. Doi: 10.1161/hc4601.097997.
[400] Kuperstein R., Klempfner R., Ofek E., Maor E., Freimark D., Sternik L., Goldenberg I., Raanani E., Arad M. De novo mitral regurgitation as a cause of heart failure exacerbation in patients with hypertrophic cardiomyopathy. Int J Cardiol 2018; 252: 122–7. Doi: 10.1016/J.IJCARD.2017.11.060.
[401] Subramanian M., Sravani V., Krishna SP., Bijjam S., Sunehra C., Yalagudri S., Saggu DK., Narasimhan C. Efficacy of SGLT2 Inhibitors in Patients With Diabetes and Nonobstructive Hypertrophic Cardiomyopathy. Am J Cardiol 2023; 188: 80–6. Doi: 10.1016/J.AMJCARD.2022.10.054.
[402] Maron MS., Chan RH., Kapur NK., Jaffe IZ., McGraw AP., Kerur R., Maron BJ., Udelson JE. Effect of Spironolactone on Myocardial Fibrosis and Other Clinical Variables in Patients with Hypertrophic Cardiomyopathy. Am J Med 2018; 131(7): 837–41. Doi: 10.1016/j.amjmed.2018.02.025.
[403] Olivotto I., Oreziak A., Barriales-Villa R., Abraham TP., Masri A., Garcia-Pavia P., Saberi S., Lakdawala NK., Wheeler MT., Owens A., et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England) 2020; 396(10253): 759–69. Doi: 10.1016/S0140-6736(20)31792-X.
[404] Pelliccia F., Cecchi F., Olivotto I., Camici PG. Microvascular Dysfunction in Hypertrophic Cardiomyopathy. J Clin Med 2022; 11(21): 6560. Doi: 10.3390/JCM11216560.
[405] Cannon RO., Rosing DR., Maron BJ., Leon MB., Bonow RO., Watson RM., Epstein SE. Myocardial ischemia in patients with hypertrophic cardiomyopathy: contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures. Circulation 1985; 71(2): 234–43. Doi: 10.1161/01.CIR.71.2.234.
[406] Krams R., Kofflard MJM., Duncker DJ., Von Birgelen C., Carlier S., Kliffen M., Ten Cate FJ., Serruys PW. Decreased coronary flow reserve in hypertrophic cardiomyopathy is related to remodeling of the coronary microcirculation. Circulation 1998; 97(3): 230–3. Doi: 10.1161/01.CIR.97.3.230.
[407] Shariat M., Thavendiranathan P., Nguyen E., Wintersperger B., Paul N., Rakowski H., Crean AM. Utility of coronary CT angiography in outpatients with hypertrophic cardiomyopathy presenting with angina symptoms. J Cardiovasc Comput Tomogr 2014; 8(6): 429–37. Doi: 10.1016/J.JCCT.2014.09.007.
[408] van der Velde N., Huurman R., Yamasaki Y., Kardys I., Galema TW., Budde RP., Zijlstra F., Krestin GP., Schinkel AF., Michels M., et al. Frequency and Significance of Coronary Artery Disease and Myocardial Bridging in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol 2020; 125(9): 1404–12. Doi: 10.1016/J.AMJCARD.2020.02.002.
[409] Dias A., Núñez Gil IJ., Santoro F., Madias JE., Pelliccia F., Brunetti ND., Salmoirago-Blotcher E., Sharkey SW., Eitel I., Akashi YJ., et al. Takotsubo syndrome: State-of-the-art review by an expert panel - Part 2. Cardiovasc Revasc Med 2019; 20(2): 153–66. Doi: 10.1016/J.CARREV.2018.11.016.
[410] Pelliccia F., Limongelli G., Autore C., Gimeno-Blanes JR., Basso C., Elliott P. Sex-related differences in cardiomyopathies. Int J Cardiol 2019; 286: 239–43. Doi: 10.1016/J.IJCARD.2018.10.091.
[411] Crea F., Camici PG., Merz CNB. Coronary microvascular dysfunction: an update. Eur Heart J 2014; 35(17): 1101–11. Doi: 10.1093/EURHEARTJ/EHT513.
[412] Puwanant S., Trongtorsak A., Wanlapakorn C., Songsirisuk N., Ariyachaipanich A., Boonyaratavej S. Acute coronary syndrome with non-obstructive coronary arteries (ACS-NOCA) in patients with hypertrophic cardiomyopathy. BMC Cardiovasc Disord 2021; 21(1): 556. Doi: 10.1186/S12872-021-02373-Z.
[413] Barbarash OL., Karpov YA., Kashtalap V V., Boschenko AA., Ruda MM., Akchurin RS., Alekyan BG., Aronov DM., Belenkov YN., Boytsov SA., et al. 2020 Clinical practice guidelines for Stable coronary artery disease. Russ J Cardiol 2020; 25(11): 201–50. Doi: 10.15829/29/1560-4071-2020-4076.
[414] Kunadian V., Chieffo A., Camici PG., Berry C., Escaned J., Maas AHEM., Prescott E., Karam N., Appelman Y., Fraccaro C., et al. An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. Eur Heart J 2020; 41(37): 3504–20. Doi: 10.1093/EURHEARTJ/EHAA503.
[415] Knuuti J., Wijns W., Saraste A., Capodanno D., Barbato E., Funck-Brentano, C Prescott E., Storey R., Deaton C., Cuisset T., Agewall S., et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020; 41(3): 407–77. Doi: 10.1093/EURHEARTJ/EHZ425.
[416] Dybro AM., Rasmussen TB., Nielsen RR., Andersen MJ., Jensen MK., Poulsen SH. Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol 2021; 78(25): 2505–17. Doi: 10.1016/J.JACC.2021.07.065.
[417] Wilmshurst PT., Thompson DS., Juul SM., Jenkins BS., Webb-Peploe MM. Effects of verapamil on haemodynamic function and myocardial metabolism in patients with hypertrophic cardiomyopathy. Heart 1986; 56(6): 544–53. Doi: 10.1136/hrt.56.6.544.
[418] Petkow Dimitrow P., Krzanowski M., Nizankowski R., Szczeklik A., Dubiel JS. Effect of verapamil on systolic and diastolic coronary blood flow velocity in asymptomatic and mildly symptomatic patients with hypertrophic cardiomyopathy. Heart 2000; 83(3): 262–6. Doi: 10.1136/HEART.83.3.262.
[419] Mengesha HG., Weldearegawi B., Petrucka P., Bekele T., Otieno MG., Hailu A. Effect of ivabradine on cardiovascular outcomes in patients with stable angina: meta-analysis of randomized clinical trials. BMC Cardiovasc Disord 2017; 17(1): 105. Doi: 10.1186/S12872-017-0540-3.
[420] European Medicines Agency recommends measures to reduce risk of heart problems with Corlentor/Procoralan (ivabradine) | European Medicines Agency. https://www.ema.europa.eu/en/news/european-medicines-agency-recommends-measures-reduce-risk-heart-problems-corlentorprocoralan. [accessed April 26, 2023].
[421] Gupta T., Harikrishnan P., Kolte D., Khera S., Aronow WS., Mujib M., Palaniswamy C., Sule S., Jain D., Ahmed A., et al. Outcomes of acute myocardial infarction in patients with hypertrophic cardiomyopathy. Am J Med 2015; 128(8): 879-887.e1. Doi: 10.1016/J.AMJMED.2015.02.025.
[422] Thygesen K., Alpert JS., Jaffe AS., Chaitman BR., Bax JJ., Morrow DA., White HD., Corbett S., Chettibi M., Hayrapetyan H., et al. Fourth Universal Definition of Myocardial Infarction (2018). Circulation 2018; 138(20): e618–51. Doi: 10.1161/CIR.0000000000000617.
[423] Yang YJ., Fan CM., Yuan JQ., Zhang H Bin., Duan FJ., Wang ZM., Guo XY., Zhai SS., An SY., Hang F., et al. Long-term survival after acute myocardial infarction in patients with hypertrophic cardiomyopathy. Clin Cardiol 2017; 40(1): 26–31. Doi: 10.1002/CLC.22601.
[424] Tamis-Holland JE., Jneid H., Reynolds HR., Agewall S., Brilakis ES., Brown TM., Lerman A., Cushman M., Kumbhani DJ., Arslanian-Engoren C., et al. Contemporary Diagnosis and Management of Patients With Myocardial Infarction in the Absence of Obstructive Coronary Artery Disease: A Scientific Statement From the American Heart Association. Circulation 2019; 139(18): E891–908. Doi: 10.1161/CIR.0000000000000670.
[425] Russian Society of Cardiology (RSC). 2020 Clinical practice guidelines for Acute ST-segment elevation myocardial infarction. Russ J Cardiol 2020; 25(11): 4103. Doi: 10.15829/29/1560-4071-2020-4103.
[426] Barbarash OL., Duplyakov D V., Zateischikov DA., Panchenko EP., Shakhnovich RM., Yavelov IS., Yakovlev AN., Abugov SA., Alekyan BG., Arkhipov M V., et al. 2020 clinical practice guidelines for acute coronary syndrome without st segment elevation. Russ J Cardiol 2021; 26(4): 149–202. Doi: 10.15829/1560-4071-2021-4449.
[427] De Filippo O., Russo C., Manai R., Borzillo I., Savoca F., Gallone G., Bruno F., Ahmad M., De Ferrari GM., D’Ascenzo F. Impact of secondary prevention medical therapies on outcomes of patients suffering from Myocardial Infarction with NonObstructive Coronary Artery disease (MINOCA): A meta-analysis. Int J Cardiol 2022; 368(1): 1–9. Doi: 10.1016/J.IJCARD.2022.08.034.
[428] Samaras A., Papazoglou AS., Balomenakis C., Bekiaridou A., Moysidis D V., Rampidis GP., Kampaktsis PN., Apostolidou-Kiouti F., Haidich A-B., Kassimis G., et al. Prognostic impact of secondary prevention medical therapy following myocardial infarction with non-obstructive coronary arteries: a Bayesian and frequentist meta-analysis. Eur Hear J Open 2022; 2(6): 077. Doi: 10.1093/EHJOPEN/OEAC077.
[429] Abdu FA., Liu L., Mohammed AQ., Xu B., Yin G., Xu S., Xu Y., Che W. Effect of Secondary Prevention Medication on the Prognosis in Patients With Myocardial Infarction With Nonobstructive Coronary Artery Disease. J Cardiovasc Pharmacol 2020; 76(6): 678–83. Doi: 10.1097/FJC.0000000000000918.
[430] Paolisso P., Bergamaschi L., Saturi G., D’Angelo EC., Magnani I., Toniolo S., Stefanizzi A., Rinaldi A., Bartoli L., Angeli F., et al. Secondary Prevention Medical Therapy and Outcomes in Patients With Myocardial Infarction With Non-Obstructive Coronary Artery Disease. Front Pharmacol 2020; 10: 1606. Doi: 10.3389/FPHAR.2019.01606.
[431] Bossard M., Gao P., Boden W., Steg G., Tanguay JF., Joyner C., Granger CB., Kastrati A., Faxon D., Budaj A., et al. Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease. Heart 2021; 107(21): 1739–47. Doi: 10.1136/HEARTJNL-2020-318045.
[432] Острый коронарный синдром без подъема сегмента ST электрокардиограммы. Клинические рекомендации 2024. https://cr.minzdrav.gov.ru/preview-cr/154_4.
[433] Кобалава ЖД., Конради АО., Недогода СВ., Шляхто ЕВ., Арутюнов ГП., Баранова ЕИ., Барбараш ОЛ., Бобкова НВ., Бойцов СА., Бубнова МГ., et al. Артериальная гипертензия у взрослых. Клинические рекомендации 2024. Российский Кардиологический Журнал 2024; 29(9): 6117. Doi: https://doi.org/10.15829/1560-4071-2024-6117.
[434] Rosing DR., Idänpään-Heikkilä U., Maron BJ., Bonow RO., Epstein SE. Use of calcium-channel blocking drugs in hypertrophic cardiomyopathy. Am J Cardiol 1985; 55(3). Doi: 10.1016/0002-9149(85)90630-7.
[435] Betocchi S., Piscione F., Losi MA., Pace L., Boccalatte M., Perrone-Filardi P., Cappelli-Bigazzi M., Briguori C., Manganelli F., Ciampi Q., et al. Effects of diltiazem on left ventricular systolic and diastolic function in hypertrophic cardiomyopathy. Am J Cardiol 1996; 78(4): 451–7. Doi: 10.1016/S0002-9149(96)00336-0.
[436] López-Sendón J., Swedberg K., McMurray J., Tamargo J., Maggioni A., Dargie H., Tendera M., Waagstein F., Kjekshus J., Lechat P., et al. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 2004; 25(15): 1341–62. Doi: 10.1016/J.EHJ.2004.06.002.
[437] Maron BJ. Hypertrophic Cardiomyopathy: A Systematic Review. JAMA 2002; 287(10): 1308–20.
[438] Maron BJ., Olivotto I., Bellone P., Conte MR., Cecchi F., Flygenring BP., Casey SA., Gohman TE., Bongioanni S., Spirito P. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 39(2): 301–7. Doi: 10.1016/S0735-1097(01)01727-2.
[439] January CT., Wann LS., Calkins H., Chen LY., Cigarroa JE., Cleveland JC., Ellinor PT., Ezekowitz MD., Field ME., Furie KL., et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart R. J Am Coll Cardiol 2019; 74(1): 104–32. Doi: 10.1016/J.JACC.2019.01.011.
[440] Di Cori A., Lilli A., Zucchelli G., Zaca V. Role of cardiac electronic implantable device in the stratification and management of embolic risk of silent atrial fibrillation: are all atrial fibrillations created equal? Expert Rev Cardiovasc Ther 2018; 16(3): 175–81. Doi: 10.1080/14779072.2018.1438267.
[441] Camm CF., Camm AJ. Atrial fibrillation and anticoagulation in hypertrophic cardiomyopathy. Arrhythmia Electrophysiol Rev 2017; 6(2): 63–8. Doi: 10.15420/aer.2017.4.2.
[442] Miller CAS., Maron MS., Estes NAM., Price LL., Rowin EJ., Maron BJ., Link MS. Safety, Side Effects and Relative Efficacy of Medications for Rhythm Control of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Am J Cardiol 2019; 123(11): 1859–62. Doi: 10.1016/j.amjcard.2019.02.051.
[443] Гринева ЕН., Цой УА., Каронова ТЛ., Андрейченко ТВ., Богданова ГА., Ванушко ВЭ., Далматова АБ., Данилов ИН., Иваниха ЕВ., Лебедев ДС., et al. Проект федеральных клинических рекомендаций по диагностике и лечению амиодарон-индуцированной дисфункции щитовидной железы. Клиническая и Экспериментальная Тиреоидология 2020; 16(2): 12–24. Doi: 10.14341/KET12693.
[444] Bartalena L., Bogazzi F., Chiovato L., Hubalewska-Dydejczyk A., Links TP., Vanderpump M. 2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction. Eur Thyroid J 2018; 7(2): 55–66. Doi: 10.1159/000486957.
[445] Theodoraki A., Vanderpump MPJ. Thyrotoxicosis associated with the use of amiodarone: the utility of ultrasound in patient management. Clin Endocrinol (Oxf) 2016; 84(2): 172–6. Doi: 10.1111/CEN.12988.
[446] Zhou YY., He W., Zhou YY., Zhu W. Non-vitamin K antagonist oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation: a systematic review and meta-analysis. J Thromb Thrombolysis 2020; 50(2): 311–7. Doi: 10.1007/s11239-019-02008-3.
[447] Lee HJ., Kim HK., Jung JH., Han K Do., Lee H., Park JB., Kim HM., Kim YJ., Ommen SR. Novel Oral Anticoagulants for Primary Stroke Prevention in Hypertrophic Cardiomyopathy Patients with Atrial Fibrillation. Stroke 2019; 50(9): 2582–6. Doi: 10.1161/STROKEAHA.119.026048.
[448] Dominguez F., Climent V., Zorio E., Ripoll-Vera T., Salazar-Mendiguchía J., García-Pinilla JM., Urbano-Moral JA., Fernández-Fernández X., Lopez-Cuenca D., Ajo-Ferrer R., et al. Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation. Int J Cardiol 2017; 248: 232–8. Doi: 10.1016/j.ijcard.2017.08.010.
[449] Li B., Sun C., Qin F., Liu N., Wu Z., Liu Q. Could direct oral anticoagulants be an alternative to vitamin K antagonists in patients with hypertrophic cardiomyopathy and atrial fibrillation? Int J Cardiol 2018; 256: 39. Doi: 10.1016/j.ijcard.2017.10.113.
[450] Lozier MR., Sanchez AM., Lee JJ., Donath EM., Font VE., Escolar E. Thromboembolic outcomes of different anticoagulation strategies for patients with atrial fibrillation in the setting of hypertrophic cardiomyopathy: A systematic review. J Atr Fibrillation 2019; 12(4): 2207. Doi: 10.4022/jafib.2207.
[451] Pisters R., Lane DA., Nieuwlaat R., De Vos CB., Crijns HJGM., Lip GYH., Andresen D., Camm AJ., Davies W., Capucci A., et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The euro heart survey. Chest 2010; 138(5): 1093–100. Doi: 10.1378/chest.10-0134.
[452] Veselka J., Faber L., Liebregts M., Cooper R., Januska J., Kashtanov M., Dabrowski M., Hansen PR., Seggewiss H., Hansvenclova E., et al. Short- and long-term outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy in patients with mild left ventricular hypertrophy: a propensity score matching analysis. Eur Hear J 2019; 40(21): 1681–7.
[453] Каштанов МГ., Чернышев СД., Кардапольцев ЛВ., Бердников СВ., Идов ЭМ. Этаноловая септальная аблация в лечении обструктивной гипертрофической кардиомиопатии : отбор пациентов и рациональность ее применения. Патология Кровообращения и Кардиохирургия 2017; 21(1): 104–16.
[454] Ommen SR., Maron BJ., Olivotto I., Maron MS., Cecchi F., Betocchi S., Gersh BJ., Ackerman MJ., McCully RB., Dearani JA., et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 46(3): 470–6. Doi: 10.1016/J.JACC.2005.02.090.
[455] Mitra A., Ghosh RK., Bandyopadhyay D., Ghosh GC., Kalra A., Lavie CJ. Significance of Pulmonary Hypertension in Hypertrophic Cardiomyopathy. Curr Probl Cardiol 2020; 45(6): 00398. Doi: 10.1016/J.CPCARDIOL.2018.10.002.
[456] Desai MY., Bhonsale A., Patel P., Naji P., Smedira NG., Thamilarasan M., Lytle BW., Lever HM. Exercise echocardiography in asymptomatic HCM: exercise capacity, and not LV outflow tract gradient predicts long-term outcomes. JACC Cardiovasc Imaging 2014; 7(1): 26–36. Doi: 10.1016/J.JCMG.2013.08.010.
[457] Nguyen A., Schaff H V., Nishimura RA., Dearani JA., Geske JB., Lahr BD., Ommen SR. Determinants of Reverse Remodeling of the Left Atrium After Transaortic Myectomy. Ann Thorac Surg 2018; 106(2): 447–53. Doi: 10.1016/j.athoracsur.2018.03.039.
[458] Finocchiaro G., Haddad F., Kobayashi Y., Lee D., Pavlovic A., Schnittger I., Sinagra G., Magavern E., Myers J., Froelicher V., et al. Impact of Septal Reduction on Left Atrial Size and Diastole in Hypertrophic Cardiomyopathy. Echocardiography 2016; 33(5): 686–94. Doi: 10.1111/ECHO.13158.
[459] Blackshear JL., Stark ME., Agnew RC., Moussa ID., Safford RE., Shapiro BP., Waldo OA., Chen D. Remission of recurrent gastrointestinal bleeding after septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy-associated acquired von Willebrand syndrome. J Thromb Haemost 2015; 13(2): 191–6. Doi: 10.1111/JTH.12780.
[460] Desai MY., Smedira NG., Dhillon A., Masri A., Wazni O., Kanj M., Sato K., Thamilarasan M., Popovic ZB., Lever HM. Prediction of sudden death risk in obstructive hypertrophic cardiomyopathy: Potential for refinement of current criteria. J Thorac Cardiovasc Surg 2018; 156(2): 750-759.e3. Doi: 10.1016/J.JTCVS.2018.03.150.
[461] McLeod CJ., Ommen SR., Ackerman MJ., Weivoda PL., Shen WK., Dearani JA., Schaff H V., Tajik AJ., Gersh BJ. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. Eur Heart J 2007; 28(21): 2583–8. Doi: 10.1093/EURHEARTJ/EHM117.
[462] Nishimura RA., Otto CM., Bonow RO., Carabello BA., Erwin JP., Fleisher LA., Jneid H., Mack MJ., McLeod CJ., O’Gara PT., et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2017; 70(2): 252–89. Doi: 10.1016/J.JACC.2017.03.011.
[463] Sorajja P., Nishimura RA., Gersh BJ., Dearani JA., Hodge DO., Wiste HJ., Ommen SR. Outcome of mildly symptomatic or asymptomatic obstructive hypertrophic cardiomyopathy: a long-term follow-up study. J Am Coll Cardiol 2009; 54(3): 234–41. Doi: 10.1016/J.JACC.2009.01.079.
[464] Ball W., Ivanov J., Rakowski H., Wigle ED., Linghorne M., Ralph-Edwards A., Williams WG., Schwartz L., Guttman A., Woo A. Long-term survival in patients with resting obstructive hypertrophic cardiomyopathy comparison of conservative versus invasive treatment. J Am Coll Cardiol 2011; 58(22): 2313–21. Doi: 10.1016/J.JACC.2011.08.040.
[465] Mestres CA., Bartel T., Sorgente A., Müller S., Gruner C., Dearani J., Quintana E. Hypertrophic Obstructive Cardiomyopathy: What, When, Why, for Whom? Eur J Cardiothorac Surg 2018; 53(4): 700–7.
[466] Хитрова МЭ., Бокерия ЛА., Берсенева МИ., Плавинский СЛ., Авдеева МВ. Метаанализ результатов хирургического лечения гипертрофической обструктивной кардиомиопатии. Креативная Кардиология 2017; 11(4): 337–47. Doi: 10.24022/1997-3187-2017-11-4-337-347.
[467] Veselka J., Jensen MK., Liebregts M., Januska J., Krejci J., Bartel T., Dabrowski M., Hansen PR., Almaas VM., Seggewiss H., et al. Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: Results from the Euro-ASA registry. Eur Heart J 2016; 37(19): 1517–23. Doi: 10.1093/eurheartj/ehv693.
[468] Bogachev-Prokophiev A., Afanasyev A., Zheleznev S., Fomenko M., Sharifulin R., Kretov E., Karaskov A. Mitral Valve Repair or Replacement in Hypertrophic Obstructive Cardiomyopathy: A Prospective Randomized Study. Interact Cardiovasc Thorac Surg 2017; 25(3): 356–62. Doi: 10.1093/ICVTS/IVX152.
[469] Bogachev-Prokophiev A., Afanasyev A V., Zheleznev S., Pivkin A., Sharifulin R., Kozmin D., Karaskov A. Septal Myectomy With Vs Without Subvalvular Apparatus Intervention in Patients With Hypertrophic Obstructive Cardiomyopathy: A Prospective Randomized Study. Semin Thorac Cardiovasc Surg 2019; 31(3): 424–31. Doi: 10.1053/j.semtcvs.2019.01.011.
[470] Afanasyev A., A. B-P., E. L., R. S., M. O., D. K., A. K. Myectomy With Mitral Valve Repair Versus Replacement in Adult Patients With Hypertrophic Obstructive Cardiomyopathy: A Systematic Review and Meta-Analysis. Interact Cardiovasc Thorac Surg 2019; 28(3): 465–72. Doi: 10.1093/ICVTS/IVY269.
[471] Гурщенков АВ., Сухова ИВ., Зайцев ВВ., Майстренко АД., Дьяченко ЯА., Агаев РС., Уртемеев ОВ., Моисеева ОМ., Новиков ВК., Кучеренко ВС., et al. Пятилетний опыт использования мобилизации сердца при септальной миоэктомии. Кардиология и Сердечно-Сосудистая Хирургия 2018; 11(4): 54–8.
[472] Morrow AG., Reitz BA., Epstein SE., Henry WL., Conkle DM., Itscoitz SB., Redwood DR. Operative treatment in hypertrophic subaortic stenosis. Techniques, and the results of pre and postoperative assessments in 83 patients. Circulation 1975; 52(1): 88–102. Doi: 10.1161/01.CIR.52.1.88.
[473] Messmer BJ., Klues HG., Reith S., Schoendube FA., Hanrath P. Hypertrophic obstructive cardiomyopathy. Adv Card Surg 1998; 10: 245–70.
[474] Хитрова МЭ., Бокерия ЛА., Берсенева МИ., Маленков ДА. Клинические случаи успешного хирургического лечения гипертрофической обструктивной кардиомиопатии с митральной недостаточностью и sam-синдромом, выполненного методом миэктомии межжелудочковой перегородки из правого желудочка. Бюллетень НЦССХ Им АН Бакулева РАМН 2017; 18(6): 609–17.
[475] Sun D., Schaff H V., Nishimura RA., Geske JB., Dearani JA., Ommen SR. Transapical Septal Myectomy for Hypertrophic Cardiomyopathy With Midventricular Obstruction. Ann Thorac Surg 2021; 111(3): 836–44. Doi: 10.1016/J.ATHORACSUR.2020.05.182.
[476] Tang Y., Song Y., Duan F., Deng L., Ran J., Gao G., Liu S., Liu Y., Wang H., Zhao S., et al. Extended myectomy for hypertrophic obstructive cardiomyopathy patients with midventricular obstruction. Eur J Cardiothorac Surg 2018; 54(5): 875–83. Doi: 10.1093/EJCTS/EZY203.
[477] Borisov K V. Right ventricle myectomy. Ann Cardiothorac Surg 2017; 6(4): 402–9. Doi: 10.21037/acs.2017.07.10.
[478] Wehman B., Ghoreishi M., Foster N., Wang L., D’Ambra MN., Maassel N., Maghami S., Quinn R., Dawood M., Fisher S., et al. Transmitral Septal Myectomy for Hypertrophic Obstructive Cardiomyopathy. Ann Thorac Surg 2018; 105(4): 1102–8. Doi: 10.1016/j.athoracsur.2017.10.045.
[479] Бокерия ЛА. Гипертрофическая обструктивная кардиомиопатия. Анналы Хирургии 2013; 5: 5–14.
[480] Takahashi J., Wakamatsu Y., Okude J., Gohda T., Sanefuji Y., Kanaoka T., Sasaki S., Matsui Y. Septal Myectomy, Papillary Muscle Resection, and Mitral Valve Replacement for Hypertrophic Obstructive Cardiomyopathy: A Case Report. Ann Thorac Cardiovasc Surg 2008; 14(4): 258–62.
[481] Holst KA., Hanson KT., Ommen SR., Nishimura RA., Habermann EB., Schaff H V. Septal Myectomy in Hypertrophic Cardiomyopathy: National Outcomes of Concomitant Mitral Surgery. Mayo Clin Proc 2019; 94(1): 66–73. Doi: 10.1016/J.MAYOCP.2018.07.022.
[482] Hong JH., Schaff H V., Nishimura RA., Abel MD., Dearani JA., Li Z., Ommen SR. Mitral Regurgitation in Patients With Hypertrophic Obstructive Cardiomyopathy: Implications for Concomitant Valve Procedures. J Am Coll Cardiol 2016; 68(14): 1497–504. Doi: 10.1016/J.JACC.2016.07.735.
[483] Stassano P., Tommaso L Di., Triggiani D., Contaldo A., Gagliardi C., Spampinato N. Mitral Valve Replacement and Limited Myectomy for Hypertrophic Obstructive Cardiomyopathy: A 25-Year Follow-Up. Texas Hear Inst J 2004; 31(2): 137–42.
[484] Afanasyev A V., Bogachev-Prokophiev A V., Zheleznev SI., Sharifulin RM., Zalesov AS., Budagaev SA. Edge-to-Edge Repair Versus Secondary Cord Cutting During Septal Myectomy in Patients With Hypertrophic Obstructive Cardiomyopathy: A Pilot Randomised Study. Heart Lung Circ 2021; 30(3): 438–45. Doi: 10.1016/J.HLC.2020.05.106.
[485] Ferrazzi P., Spirito P., Iacovoni A., Calabrese A., Migliorati K., Simon C., Pentiricci S., Poggio D., Grillo M., Amigoni P., et al. Transaortic Chordal Cutting: Mitral Valve Repair for Obstructive Hypertrophic Cardiomyopathy With Mild Septal Hypertrophy. J Am Coll Cardiol 2015; 66(15): 1687–96. Doi: 10.1016/J.JACC.2015.07.069.
[486] Nguyen A., Schaff H V., Nishimura RA., Geske JB., Dearani JA., King KS., Ommen SR. Apical myectomy for patients with hypertrophic cardiomyopathy and advanced heart failure. J Thorac Cardiovasc Surg 2020; 159(1): 145–52. Doi: 10.1016/J.JTCVS.2019.03.088.
[487] Afanasyev A., Bogachev-Prokophiev A., Zheleznev S., Ovcharov M., Zalesov A., Sharifulin R., Demin I., Tsaroev B., Nazarov V., Chernyavskiy A. Transapical Approach to Septal Myectomy for Hypertrophic Cardiomyopathy. Life (Basel, Switzerland) 2024; 14(1): 125. Doi: 10.3390/LIFE14010125.
[488] Афанасьев АВ., Богачев-Прокофьев АВ., Кирилова ВС., Волкова ИИ., Кашапов РИ., Шаяхметова СВ., Залесов АС., Пивкин АН., Назаров ВМ., Чернявский АМ. Трансапикальная миоэктомия как альтернатива трансплантации сердца у пациента с апикальной гипертрофической кардиомиопатией. Клиническая и Экспериментальная Хирургия Журнал Имени Академика БВ Петровского 2024; 12(1): 127–34.
[489] Boll G., Rowin EJ., Maron BJ., Wang W., Rastegar H., Maron MS. Efficacy of Combined Cox-Maze IV and Ventricular Septal Myectomy for Treatment of Atrial Fibrillation in Patients With Obstructive Hypertrophic Cardiomyopathy. Am J Cardiol 2020; 125(1): 120–6. Doi: 10.1016/J.AMJCARD.2019.09.029.
[490] Bogachev-Prokophiev A V., Afanasyev A V., Zheleznev SI., Pivkin AN., Fomenko MS., Sharifulin RM., Karaskov AM. Concomitant ablation for atrial fibrillation during septal myectomy in patients with hypertrophic obstructive cardiomyopathy. J Thorac Cardiovasc Surg 2018; 155(4): 1536-1542.e2. Doi: 10.1016/j.jtcvs.2017.08.063.
[491] Prinz C., Schwarz M., Ilic I., Laser KT., Lehmann R., Prinz EM., Bitter T., Vogt J., Van Buuren F., Bogunovic N., et al. Myocardial Fibrosis Severity on Cardiac Magnetic Resonance Imaging Predicts Sustained Arrhythmic Events in Hypertrophic Cardiomyopathy. Can J Cardiol 2013; 29(3): 358–63. Doi: 10.1016/j.cjca.2012.05.004.
[492] Sherrid M V., Massera D. Risk Stratification and Hypertrophic Cardiomyopathy Subtypes. J Am Coll Cardiol 2019; 74(19): 2346–9. Doi: 10.1016/j.jacc.2019.09.020.
[493] O’Hanlon R., Grasso A., Roughton M., Moon JC., Clark S., Wage R., Webb J., Kulkarni M., Dawson D., Sulaibeekh L., et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 2010; 56(11): 867–74. Doi: 10.1016/j.jacc.2010.05.010.
[494] Бельских ЛВ., Гичкун ОЕ., Гордеев МЛ., Готье СВ., Захаревич ВМ., Климушева НФ., Минина МГ., Миронков БЛ., Николаев ГВ., Платонов ВС., et al. Трансплантация сердца и механическая поддержка кровообращения. Национальные клинические рекомендации. 2016.
[495] Topilsky Y., Pereira NL., Shah DK., Boilson B., Schirger JA., Kushwaha SS., Joyce LD., Park SJ. Left ventricular assist device therapy in patients with restrictive and hypertrophic cardiomyopathy. Circ Hear Fail 2011; 4(3): 266–75. Doi: 10.1161/CIRCHEARTFAILURE.110.959288.
[496] Sreenivasan J., Kaul R., Khan MS., Ranka S., Demmer RT., Yuzefpolskaya M., Aronow WS., Warraich HJ., Pan S., Panza JA., et al. Left Ventricular Assist Device Implantation in Hypertrophic and Restrictive Cardiomyopathy: A Systematic Review. ASAIO J 2021; 67(3): 239–44. Doi: 10.1097/MAT.0000000000001238.
[497] Patel SR., Saeed O., Naftel D., Myers S., Kirklin J., Jorde UP., Goldstein DJ. Outcomes of Restrictive and Hypertrophic Cardiomyopathies After LVAD: An INTERMACS Analysis. J Card Fail 2017; 23(12): 859–67. Doi: 10.1016/J.CARDFAIL.2017.09.011.
[498] Yagi N., Seguchi O., Mochizuki H., Kuroda K., Nakajima S., Watanabe T., Yanase M., Tadokoro N., Fukushima S., Fujita T., et al. Implantation of ventricular assist devices in hypertrophic cardiomyopathy with left ventricular systolic dysfunction. ESC Hear Fail 2021; 8(6): 5513–22. Doi: 10.1002/EHF2.13653.
[499] Grupper A., Park SJ., Pereira NL., Schettle SD., Gerber Y., Topilsky Y., Edwards BS., Daly RC., Stulak JM., Joyce LD., et al. Role of ventricular assist therapy for patients with heart failure and restrictive physiology: Improving outcomes for a lethal disease. J Heart Lung Transplant 2015; 34(8): 1042–9. Doi: 10.1016/J.HEALUN.2015.03.012.
[500] Coutu M., Perrault LP., White M., Pelletier GB., Racine N., Poirier NC., Carrier M. Cardiac transplantation for hypertrophic cardiomyopathy: a valid therapeutic option. J Heart Lung Transplant 2004; 23(4): 413–7. Doi: 10.1016/S1053-2498(03)00225-0.
[501] Стрюк РИ., Бунин ЮА., Гурьева ВМ., Иртюга ОБ., Коков ЛС., Коломацкая ОЕ., Миосеева ОМ., Мравян СР., Чесникова АИ., Чулков ВС. Диагностика и лечение сердечно-сосудистых заболеваний при беременности 2018. Национальные рекомендации. Российский Кардиологический Журнал 2018; 3(155): 91–134.
[502] Bowyer L. The Confidential Enquiry into Maternal and Child Health (CEMACH). Saving Mothers’ Lives: reviewing maternal deaths to make motherhood safer 2003–2005. The Seventh Report of the Confidential Enquiries into Maternal Deaths in the UK. Obstet Med 2008; 1(1): 54–54. Doi: 10.1258/om.2008.080017.
[503] Billebeau G., Etienne M., Cheikh-Khelifa R., Vauthier-Brouzes D., Gandjbakhch E., Isnard R., Nizard J., Komajda M., Dommergues M., Charron P. Pregnancy in women with a cardiomyopathy: Outcomes and predictors from a retrospective cohort. Arch Cardiovasc Dis 2018; 111(3): 199–209. Doi: 10.1016/j.acvd.2017.05.010.
[504] Krul SP., van der Smagt JJ., van den Berg MP., Sollie KM., Pieper PG., Spaendonck-Zwarts KY. Systematic Review of Pregnancy in Women With Inherited Cardiomyopathies. Eur J Hear Fail 2011; 13: 584–94.
[505] Regitz-Zagrosek V., Roos-Hesselink JW., Bauersachs J., Blomström-Lundqvist C., Cífková R., De Bonis M., Iung B., Johnson MR., Kintscher U., Kranke P., et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018; 39(34): 3165–241. Doi: 10.1093/eurheartj/ehy340.
[506] Приказ Министерства здравоохранения и социального развития РФ от 03.12.2007 N 736 “Об утверждении перечня медицинских показаний для искусственного прерывания беременности” (в ред. приказа Минздравсоцразвития России от 27 декабря 2011 г. N 1661н). n.d.
[507] Regitz-Zagrosek V., Blomstrom Lundqvist C., Borghi C., Cifkova R., Ferreira R., Foidart JM., Gibbs JSR., Gohlke-Baerwolf C., Gorenek B., Iung B., et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2011; 32(24): 3147–97. Doi: 10.1093/EURHEARTJ/EHR218.
[508] Schaufelberger M. Cardiomyopathy and pregnancy. Heart 2019; 105(20): 1543–51. Doi: 10.1136/heartjnl-2018-313476.
[509] Goland S., Hagen IM van., Elbaz-Greener G., Elkayam U., Shotan A., Merz WM., Enar SC., Gaisin IR., Pieper PG., Johnson MR., et al. Pregnancy in women with hypertrophic cardiomyopathy: data from the European Society of Cardiology initiated Registry of Pregnancy and Cardiac disease (ROPAC). Eur Hear J 2017; 38(35): 2683–90.
[510] Pieper PG., Walker F. Pregnancy in women with hypertrophic cardiomyopathy. Neth Heart J 2013; 21(1): 14–8. Doi: 10.1007/S12471-012-0358-7.
[511] Lee MS., Chen W., Zhang Z., Duan L., Ng A., Spencer HT., Kwan DM., Shen AYJ. Atrial Fibrillation and Atrial Flutter in Pregnant Women-A Population-Based Study. J Am Heart Assoc 2016; 5(4): e003182. Doi: 10.1161/JAHA.115.003182.
[512] Tromp CHN., Nanne ACM., Pernet PJM., Tukkie R., Bolte AC. Electrical cardioversion during pregnancy: Safe or not? Netherlands Hear J 2011; 19(3): 134–6. Doi: 10.1007/s12471-011-0077-5.
[513] Miyoshi T., Kamiya CA., Katsuragi S., Ueda H., Kobayashi Y., Horiuchi C., Yamanaka K., Neki R., Yoshimatsu J., Ikeda T., et al. Safety and efficacy of implantable cardioverter-defibrillator during pregnancy and after delivery. Circ J 2013; 77(5): 1166–70. Doi: 10.1253/CIRCJ.CJ-12-1275.
[514] Elliott P., Spirito P. Prevention of hypertrophic cardiomyopathy-related deaths: Theory and practice. Heart 2008; 94(10): 1269–75. Doi: 10.1136/hrt.2008.154385.
[515] Elliott PM., Gimeno JR., Thaman R., Shah J., Ward D., Dickie S., Esteban MTT., McKenna WJ. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart 2006; 92(6): 785–91. Doi: 10.1136/hrt.2005.068577.
[516] Maron BJ., Gardin JM., Flack JM., Gidding SS., Kurosaki TT., Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: Echocardiographic analysis of 4111 subjects in the CARDIA study. Circulation 1995; 92(4): 785–9. Doi: 10.1161/01.CIR.92.4.785.
[517] Robinson K., Frenneaux MP., Stockins B., Karatasakis G., Poloniecki JD., Mckenna WJ. Atrial fibrillation in hypertrophie cardiomyopathy: A longitudinal study. J Am Coll Cardiol 1990; 15(6): 1279–85. Doi: 10.1016/S0735-1097(10)80014-2.
[518] Monserrat L., Elliott PM., Gimeno JR., Sharma S., Penas-Lado M., McKenna WJ. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: An independent marker of sudden death risk in young patients. J Am Coll Cardiol 2003; 42(5): 873–9. Doi: 10.1016/S0735-1097(03)00827-1.
[519] Todiere G., Aquaro GD., Piaggi P., Formisano F., Barison A., Masci PG., Strata E., Bacigalupo L., Marzilli M., Pingitore A., et al. Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2012; 60(10): 922–9. Doi: 10.1016/j.jacc.2012.03.076.
[520] Burton H., Alberg C., Stewart A. Heart to Heart: Inherited Cardiovascular Conditions Services - A Needs Assessment and Service Review. 2009.
[521] Maron BJ., Nishimura RA., Maron MS. Shared decision-making in HCM. Nat Rev Cardiol 2017; 14(3): 125–6. Doi: 10.1038/NRCARDIO.2017.6.
[522] Monda E., Limongelli G. The hospitalizations in hypertrophic cardiomyopathy: “The dark side of the moon.” Int J Cardiol 2020; 318: 101–2. Doi: 10.1016/J.IJCARD.2020.08.054.
[523] Matsubara K., Nakamura T., Kuribayashi T., Azuma A., Nakagawa M. Sustained cavity obliteration and apical aneurysm formation in apical hypertrophic cardiomyopathy. J Am Coll Cardiol 2003; 42(2): 288–95. Doi: 10.1016/S0735-1097(03)00576-X.
[524] Eriksson MJ., Sonnenberg B., Woo A., Rakowski P., Parker TG., Wigle ED., Rakowski H. Long-term outcome in patients with apical hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 39(4): 638–45. Doi: 10.1016/S0735-1097(01)01778-8.
[525] Chen CC., Lei MH., Hsu YC., Chung SL., Sung YJ. Apical hypertrophic cardiomyopathy: correlations between echocardiographic parameters, angiographic left ventricular morphology, and clinical outcomes. Clin Cardiol 2011; 34(4): 233–8. Doi: 10.1002/CLC.20874.
[526] Hughes RK., Knott KD., Malcolmson J., Augusto JB., Mohiddin SA., Kellman P., Moon JC., Captur G. Apical Hypertrophic Cardiomyopathy: The Variant Less Known. J Am Heart Assoc 2020; 9(5): e015294. Doi: 10.1161/JAHA.119.015294.
[527] Deva DP., Hanneman K., Li Q., Ng MY., Wasim S., Morel C., Iwanochko RM., Thavendiranathan P., Crean AM. Cardiovascular magnetic resonance demonstration of the spectrum of morphological phenotypes and patterns of myocardial scarring in Anderson-Fabry disease. J Cardiovasc Magn Reson 2016; 18(1): 14. Doi: 10.1186/S12968-016-0233-6.
[528] Ünlü S., Özden Tok Ö., Avcı Demir F., Papadopoulos K., Monaghan MJ. Differential diagnosis of apical hypertrophic cardiomyopathy and apical displacement of the papillary muscles: a multimodality imaging point of view. Echocardiography 2021; 38(1): 103–13. Doi: 10.1111/ECHO.14895.
[529] Ruberg FL., Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation 2012; 126(10): 1286–300. Doi: 10.1161/CIRCULATIONAHA.111.078915.
[530] Efthimiadis GK., Pagourelias ED., Gossios T., Zegkos T. Hypertrophic cardiomyopathy in 2013: Current speculations and future perspectives. World J Cardiol 2014; 6(2): 26–37. Doi: 10.4330/wjc.v6.i2.26.
[531] Canepa M., Pozios I., Vianello PF., Ameri P., Brunelli C., Ferrucci L., Abraham TP. Distinguishing ventricular septal bulge versus hypertrophic cardiomyopathy in the elderly. Heart 2016; 102(14): 1087–94. Doi: 10.1136/heartjnl-2015-308764.
[532] Efthimiadis GK., Pagourelias E., Zegkos T., Parcharidou D., Panagiotidis T., Arvanitaki A., Rouskas P., Karvounis H. An Overview of Pharmacotherapy in Hypertrophic Cardiomyopathy: Current Speculations and Clinical Perspectives. Rev Cardiovasc Med 2016; 17(3–4): 115–23.
Комментарии • 0
Чтобы оставить комментарий, пожалуйста, войдите на портал